Title Page

Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial)

Anup Agarwal, Aparna Mukherjee, Gunjan Kumar, Pranab Chatterjee, Tarun Bhatnagar, Pankaj Malhotra and PLACID Trial Collaborators

The names and affiliations of PLACID Trial Collaborators are provided in Annexure 1

Running title: Convalescent plasma in COVID-19

Corresponding Author:

Name: Dr. Aparna Mukherjee MD, PhD Affiliation: Scientist-E, Clinical Trial and Health Systems Research Unit, Indian Council of Medical Research

Full Address:

Indian Council of Medical Research V. Ramalingaswamy Bhawan PO Box No. 4911 Ansari Nagar, New Delhi – 110029, India

Email:

aparna.sinha.deb@gmail.com aparna.sinha.deb@icmr.gov.in

Name	Highest Degree	Affiliation	Full Address
Anup Agarwal	MBBS	Consultant, Clinical Trial & Health Systems Research Unit, Indian Council of Medical Research (ICMR) Email – mailanupagarwal@gmail.com	Indian Council of Medical Research. V. Ramalingaswami Bhawan, P.O. Box No. 4911. Ansari Nagar, New Delhi - 110029, India.
Aparna Mukherjee	PhD	Scientist E, Clinical Trial & Health Systems Research Unit, Indian Council of Medical Research (ICMR), Email – aparna.sinha.deb@gmail.com	New Delhi - 110029, India.
Gunjan Kumar	MD	Scientist C, Clinical Trial & Health Systems Research Unit, Indian Council of Medical Research (ICMR) Email - gunjan2587@gmail.com	New Delhi - 110029, India.
Pranab Chatterjee	MD	Scientist B, Translational Global Health Policy and Research Cell, Indian Council of Medical Research (ICMR) Email - pranab.chatterjee@phi.org.in	New Delhi - 110029, India.
Tarun Bhatnagar	PhD	Scientist E, ICMR School of Public Health, Indian Council of Medical Research -National Institute of Epidemiology Email - drtarunb@gmail.com	Chennai, Tamil, India
Pankaj Malhotra	MD	Professor, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research Email – malhotrapankaj@gmail.com	Chandigarh, India
B Latha	MD	Department of Transfusion Medicine, Madras Medical College Email - latsbalu@yahoo.co.uk	Chennai, Tamil Nadu, India
Sunita Bundas	MD	Professor, Department of Immunohaematology and Transfusion Medicine, SMS Medical College and Hospital Email – drsunitabundas@yahoo.in	Jaipur, Rajasthan, India
Vivek Kumar	EDIC	Dept. of Critical Care Medicine, Sir H N Reliance Foundation Hospital Email - drvivekmd@rediffmail.com	Mumbai, India
Ravi Dosi	DNB	Professor, Department of Respiratory Medicine, Sri Aurobindo Institute of Medical Sciences Email - ravi.dosi@gmail.com	Indore, Madhya Pradesh, India
Janakkumar R Khambholja	MD	Professor, Department of Internal Medicine, Smt NHL Municipal Medical College Email - drjanak.research@gmail.com	Ahmedabad, Gujarat, India
Rosemarie de Souza	MD	Professor, Department of Internal Medicine, BYL Nair Charitable Hospital & TN Medical College Email - drrosemariedesouza@gmail.com	Mumbai, Maharashtra, India

Raja Rao Mesipogu	MD	Professor, Department of Internal Medicine, Gandhi Medical College Email - drmrrao@gmail.com	Hyderabad, Telangana, India
Saurabh Srivastava		Professor, Department of Internal Medicine, Government Institute of Medical Sciences Email - saurabhsrivas@gmail.com	Greater Noida, Uttar Pradesh, India
Simmi Dube	MD	Professor, Department of Internal Medicine, Gandhi Medical College, Bhopal Email - Simmi33@gmail.com	Bhopal, Madhya Pradesh, India
Kiran Chaudhary	MCh	Department of Transfusion Medicine, Atal Bihari Vajpayee Institute of Medical Sciences and Ram Manohar Lohia Hospital Email - drchaudharyk@yahoo.co.in	New Delhi, India
Subash S	MD	Professor, Department of Transfusion Medicine, Madras Medical College Email - dchsub@yahoo.co.in	Chennai, Tamil Nadu, India
S. Anbuselvi Mattuvar K	MD	Professor, Department of Physiology, Madras Medical College Email - dranbuselvimk@gmail.com	Chennai, Tamil Nadu, India
V Rajendran	MD	Department of Internal Medicine, Madras Medical College Email - Rsvr2003@hotmail.com	Chennai, Tamil Nadu, India
A Sundararajaperumal	MD	Department of Thoracic Medicine, Madras Medical College Email - drperumal@gmail.com	Chennai, Tamil Nadu, India
P Balamanikandan	MD	Department of Internal Medicine, Madras Medical College Email - balammc@yahoo.com	Chennai, Tamil Nadu, India
R S Uma Maheswari	MD	Department of Internal Medicine, Madras Medical College Email - drumamaheswari@gmail.com	Chennai, Tamil Nadu, India
R Jayanthi	MD	Department of Internal Medicine, Madras Medical College Email - Rjayanthi363@gmail.com	Chennai, Tamil Nadu, India
S Ragunanthanan	MD	Department of Internal Medicine, Madras Medical College Email - hemaragu@yahoo.com	Chennai, Tamil Nadu, India
Sudhir Bhandari	MD	Professor, Department of Internal Medicine, SMS Medical College and Hospital Email – drs_bhandari@yahoo.com	Jaipur, Rajasthan, India
Ajeet Singh	MD	Department of Internal Medicine, SMS Medical College and Hospital Email - Drajectsingh2020@gmail.com	Jaipur, Rajasthan, India
Ashok Pal	MD	Department of Immunohaematology and Transfusion Medicine, SMS Medical College and Hospital Email - Dr.palashok@gmail.com	Jaipur, Rajasthan, India
Anjali Handa	MD	Department of Immunohaematology and Transfusion Medicine, SMS Medical College and Hospital	Jaipur, Rajasthan, India

		Email - Ahnumero29@gmail.com	
Govind Rankawat	MBBS	Department of Internal Medicine,	Jaipur, Rajasthan, India
		SMS Medical College and Hospital	
		Email - govindrankawat@gmail.com	
Ketan Kargirwar	EDIC	Dept. of Critical Care Medicine,	Mumbai, Maharashtra,
		Sir H N Reliance Foundation Hospital	India
		Email - ketan.kargirwar@rfhospital.org	
Joyce Regi	MD	Dept. of Transfusion Medicine,	Mumbai, Maharashtra,
, ,		Sir H N Reliance Foundation Hospital	India
		Email - joyce.regi@rfhospital.org	
Darshana Rathod	MD	Dept. of Critical Care Medicine,	Mumbai, Maharashtra,
		Sir H N Reliance Foundation Hospital	India
		Email - Darshana.Rathod@rfhospital.org	
Edwin Pathrose	MBBS	Dept. of Critical Care Medicine,	Mumbai, Maharashtra,
		Sir H N Reliance Foundation Hospital	India
		Email - Edwin.Pathrose@rfhospital.org	
Nirankar Bhutaka	MBBS	Dept. of Critical Care Medicine,	Mumbai, Maharashtra,
		Sir H N Reliance Foundation Hospital	India
		Email - Nirankar.Bhutaka@rfhospital.org	
Mayur H Patel	MD	Dept. of Critical Care and Emergency Medicine,	Mumbai, Maharashtra,
1.14) 41 11 1 4001	1.12	Sir H N Reliance Foundation Hospital	India
		Email - Mayur.H.Patel@rfhospital.org	
Rahul J Verma	MRCP	Dept. of Academics and Research,	Mumbai, Maharashtra,
Tanar 5 Verma	WIRCH	Sir H N Reliance Foundation Hospital	India
		Email - Rahul.j.verma@rfhospital.org	India
Kamal Malukani	MD	Professor,	Indore, Madhya
Kamai Walakam	WID	Department of Pathology,	Pradesh, India
		Sri Aurobindo Institute of Medical Sciences	Tracesii, iliaia
		Email – <u>kamal.malukani@yahoo.com</u>	
Shivani Patel	DM	Department of Hematology,	Indore, Madhya
Sili vain 1 atei	Divi	Sri Aurobindo Institute of Medical Sciences	Pradesh, India
		Email – shivani2105@yahoo.com	Tracesii, iliaia
Apurv Thakur	MD	Department of Community Medicine,	Indore, Madhya
Tiput v Thukui	WID	Sri Aurobindo Institute of Medical Sciences	Pradesh, India
		Email – apury thakur333@yahoo.co.in	Tracesii, mara
Satish Joshi	DCP	Department of Pathology,	Indore, Madhya
Satisti Joshi	DCI	Sri Aurobindo Institute of Medical Sciences	Pradesh, India
		Email – <u>drjoshi_s@yahoo.com</u>	Tradesii, ilidia
Rashmi Kulkarni	PhD	Department of Forensic Medicine,	Indore, Madhya
Kasiiiii Kuikaiiii	FIID	Sri Aurobindo Institute of Medical Sciences	Pradesh, India
		Email - rashmiajit3@gmail.com	r radesii, fiidia
Nilay N Suthar	MD	Professor,	Ahmedabad, Gujarat,
Milay N Suulai	MID	Department of Internal Medicine,	India Gujarat,
		Smt NHL Municipal Medical College	Ilidia
		Email: nilaysuthar@gmail.com	
Nehal M Shah	MD	Department of Internal Medicine,	Ahmedabad, Gujarat,
Neliai Wi Silaii	MID		Ahmedabad, Gujarat, India
		Smt NHL Municipal Medical College	Iliula
Hamana M Danahi	MC	Email: drnehalshah1929@gmail.com	Ahmadahad Coiseet
Hemang M Purohit	MSc	Department of Internal Medicine,	Ahmedabad, Gujarat,
		Smt NHL Municipal Medical College	India
Cl IZ Cl. 1	MD	Email: hemang.research@gmail.com	A1
Cherry K Shah	MD	Professor,	Ahmedabad, Gujarat,
		Department of Pathology,	India
		Smt NHL Municipal Medical College	
		Email: drcherryshah@gmail.com	

Monila N Patel	MD	Professor,	Ahmedabad, Gujarat,
		Department of Internal Medicine,	India
		Smt NHL Municipal Medical College	
		Email: monilapatel@hotmail.com	
Sanket Shah	DM	Department of Hematology,	Ahmedabad, Gujarat,
		Smt NHL Municipal Medical College	India
		Email: drsanket2086@gmail.com	
Smit H Shah	MBBS	Department of Internal Medicine,	Ahmedabad, Gujarat,
		Smt NHL Municipal Medical College	India
		Email: smittusharshah@gmail.com	
Tehsim Memon	MBBS	Department of Internal Medicine,	Ahmedabad, Gujarat,
		Smt NHL Municipal Medical College	India
		Email: tehsimemon@gmail.com	
Vishal R Beriwala	MBBS	Department of Internal Medicine,	Ahmedabad, Gujarat,
		Smt NHL Municipal Medical College	India
		Email: vishal.r.beriwala@gmail.com	
Kusum Jashnani	MD	Professor,	Mumbai, Maharashtra,
		Department of Pathology,	India
		BYL Nair Charitable Hospital & TN Medical College	
		Email - kasumjash@hotmail.com	
Fatema Ezzy	Medical	Department of Internal Medicine,	Mumbai, Maharashtra,
,	Student	BYL Nair Charitable Hospital & TN Medical College	India
		Email - Ezzy.fatema1998@gmail.com	
Simran Agrawal	Medical	Department of Internal Medicine,	Mumbai, Maharashtra,
21111 411 1 151 4 1 41	Student	BYL Nair Charitable Hospital & TN Medical College	India
	Stagont	Email - Agrawalsimran2803@gmail.com	111010
Rakesh Bhadade	MD	Department of Internal Medicine,	Mumbai, Maharashtra,
21444	1.12	BYL Nair Charitable Hospital & TN Medical College	India
		Email - rakeshbhadade@gmail.com	man
Atish MN	MD	Department of Internal Medicine,	Mumbai, Maharashtra,
TRIBIT IVII V	1,125	BYL Nair Charitable Hospital & TN Medical College	India
		Email - Aathish329@gmail.com	man
Tushar Madke	MD	Department of Internal Medicine,	Mumbai, Maharashtra,
1 dollar 1/1adic	1,125	BYL Nair Charitable Hospital & TN Medical College	India
		Email - drtusharmadke@gmail.com	111010
Vikash Kavishwar	MD	Department of Pathology,	Mumbai, Maharashtra,
v ikusii iku visii wui	IVID	BYL Nair Charitable Hospital & TN Medical College	India
		Email - kavishwarvikas@gmail.com	man
Ramesh Waghmare	MD	Department of Pathology,	Mumbai, Maharashtra,
ramesh wagimare	IVID	BYL Nair Charitable Hospital & TN Medical College	India
		Email - rameshpathmumbai@gmail.com	man
Nitin Valvi	MD	Department of Pathology,	Mumbai, Maharashtra,
Titili valvi	1,12	BYL Nair Charitable Hospital & TN Medical College	India
		Email - Nitinvalvi02@gmail.com	man
B Thrilok Chander	MD	Department of Internal Medicine,	Secunderabad,
D THITIOR CHANGE	WID	Gandhi Medical College, Secunderabad	Telangana, India
		Email - Thrilok73@gmail.com	Totaligana, mala
A Vinaya Sekhar	MD	Professor,	Secunderabad,
A villaya Sekilai	WID	Department of Internal Medicine,	Telangana, India
		Gandhi Medical College, Secunderabad	Telangana, mala
			1
Akhilesh Kumar	MRRS	Email - <u>Drvinaya31@gmail.com</u>	Secunderahad
Akhilesh Kumar	MBBS	Email - <u>Drvinaya31@gmail.com</u> Department of Internal Medicine,	Secunderabad,
Akhilesh Kumar Maurya	MBBS	Email - <u>Drvinaya31@gmail.com</u>	Secunderabad, Telangana, India

		Gandhi Medical College, Secunderabad Email - hemanthandme@gmail.com	Telangana, India
K Nagamani	MD	Department of Microbiology,	Secunderabad,
K Magamam	WID	Gandhi Medical College, Secunderabad	Telangana, India
		Email - Nagamaniy2k03@rediffmail.com	Telangana, mena
V C. dl. a	MBBS		Canan danaha d
K Sudha	MBBS	Department of Blood Bank,	Secunderabad,
		Gandhi Medical College, Secunderabad	Telangana, India
		Email - sudhajavvaji@gmail.com	
T Ravi Chandra	MBBS	Department of Internal Medicine,	Secunderabad,
		Gandhi Medical College, Secunderabad	Telangana, India
		Email - Ravichandratata13@gmail.com	
K Tushara Rao	MBBS	Department of Internal Medicine,	Secunderabad,
		Gandhi Medical College, Secunderabad	Telangana, India
		Email - Tushara2792@gmail.com	
J Vyshnavi	MBBS	Department of Internal Medicine,	Secunderabad,
•		Gandhi Medical College, Secunderabad	Telangana, India
		Email - jamalapuramVyshnavi16@gmail.com	
Rashmi Upadhyay	MD	Assistant Professor,	Greater Noida, Uttar
Rasinin Opadnyay	IVID	Department of Pulmonary Medicine,	Pradesh, India
		Government Institute of Medical Sciences	Tradesii, mara
		Email - rash.georgian@gmail.com	
Cl1' ' D -1 1	MD		Constant Nation 1144
Shalini Bahadur	MD	Associate Professor,	Greater Noida, Uttar
		Department of Pathology,	Pradesh, India
		Government Institute of Medical Sciences	
		Email - shalini.bahadur2008@rediffmail.com	
Rambha Pathak	MD	Professor,	Greater Noida, Uttar
		Department of Community Medicine,	Pradesh, India
		Government Institute of Medical Sciences	
		Email - rambha_p@yahoo.com	
Shikha Seth	MD	Professor,	Greater Noida, Uttar
		Department of Obstetrics and Gynecology,	Pradesh, India
		Government Institute of Medical Sciences	
		Email - drseth_shikha@yahoo.com	
Brig. Rakesh Gupta	MD	Professor,	Greater Noida, Uttar
Diig. Rakesii Gupta	WID	Department of Pediatrics,	Pradesh, India
		Government Institute of Medical Sciences	Fradesii, Ilidia
D': C	100	Email - colrgupta@gmail.com	D1 1 14 11
Rita Saxena	MD	Department of Internal Medicine,	Bhopal, Madhya
		Gandhi Medical College, Bhopal	Pradesh, India
		Email - <u>ritasinghsaxena@gmail.com</u>	
Preksha Dwivedi	DM	Department of Internal Medicine,	Bhopal, Madhya
		Gandhi Medical College, Bhopal	Pradesh, India
		Email - drpreksha07@gmail.com	
Reeni Malik	MD	Professor, Department of Pathology, Gandhi Medical	Bhopal, Madhya
		College, Bhopal	Pradesh, India
		Email - reenimalik@yahoo.co.in	11440511, 111414
Deepti Chourasia	MD	Department of Microbiology,	Bhopal, Madhya
Deepti Cilourusiu	IVID	Gandhi Medical College, Bhopal	Pradesh, India
		Email - drdeeptichaurasia.09@gmail.com	i iaucsii, iliula
T T1	MD		Discussi 34 "
Jaya Lalwani	MD	Department of Microbiology,	Bhopal, Madhya
		Gandhi Medical College, Bhopal	Pradesh, India
		Email - <u>drjaya_is@yahoo.co.in</u>	
UM Sharma	MD	Department of Pathology,	Bhopal, Madhya
		Gandhi Medical College, Bhopal	Pradesh, India

JL Marko	MD	Department of Pharmacology,	Bhopal, Madhya
		Gandhi Medical College, Bhopal	Pradesh, India
	1.00	Email - <u>drjlmarko.77@gmail.com</u>	N D II : I II
Amit Suri	MD	Department of Pulmonary Medicine,	New Delhi, India
		Atal Bihari Vajpayee Institute of Medical Sciences	
		and Ram Manohar Lohia Hospital	
Y 711 Y 7	1.00	Email - agrimsuri@gmail.com	N D II : I II
Vijay Kumar	MD	Professor, Department of Pathology,	New Delhi, India
		Atal Bihari Vajpayee Institute of Medical Sciences	
		and Ram Manohar Lohia Hospital	
		Email – vijaypgi@gmail.com	
Rajnish Kaushik	DM	Department of Pulmonary Medicine,	New Delhi, India
		Atal Bihari Vajpayee Institute of Medical Sciences	
		and Ram Manohar Lohia Hospital	
		Email - drrajnishkaushik@gmail.com	
Parul Kodan	DM	Department of Internal Medicine,	New Delhi, India
		Atal Bihari Vajpayee Institute of Medical Sciences	
		and Ram Manohar Lohia Hospital	
		Email - parulkodan@yahoo.com	
Bhabani Prasad	MD	Department of Community Medicine,	New Delhi, India
Acharya		Atal Bihari Vajpayee Institute of Medical Sciences	
•		and Ram Manohar Lohia Hospital	
		Email - <u>bhabani.prasad87@gmail.com</u>	
Kuldeep Kumar Gaur	MBBS	Department of Internal Medicine,	New Delhi, India
		Atal Bihari Vajpayee Institute of Medical Sciences	
		and Ram Manohar Lohia Hospital	
		Email - kuldeepgaur93@gmail.com	
Anubhav Gupta	MD	Department of Transfusion Medicine,	New Delhi, India
Tindona V Gapta	IVID	Atal Bihari Vajpayee Institute of Medical Sciences	Tiew Benn, maia
		and Ram Manohar Lohia Hospital	
		Email - dr.anubhavgupta@yahoo.com	
Prerna Sachdeva	MD	Department of Transfusion Medicine,	New Delhi, India
i iema Saendeva	MID	Atal Bihari Vajpayee Institute of Medical Sciences	New Denn, maia
		and Ram Manohar Lohia Hospital	
		Email - sachdevaprerna86@gmail.com	
Shruti Dogra	MD	Department of Pathology,	New Delhi, India
Silruti Dogra	MD	1	New Deini, India
		Atal Bihari Vajpayee Institute of Medical Sciences	
		and Ram Manohar Lohia Hospital	
A'1 ' T' 1 1	MD	Email - d.shrutidogra@gmail.com	I II: D : I I I:
Aikaj Jindal	MD	Department of Transfusion Medicine,	Ludhiana, Punjab, India
		Satguru Partap Singh Hospitals,	
161	D) (Email – <u>drjindalaikaj@gmail.com</u>	
M Joseph John	DM	Professor,	Ludhiana, Punjab, India
		Department of Clinical Hematology, Christian	
		Medical College	
		Email – mjosephjohn@gmail.com	
Avtar Singh Dhanju	MD	Professor,	Amritsar, Punjab, India
		Department of Internal Medicine, Government	
		Medical College, Amritsar	
		Email – avtar.dhanju.ad@gmail.com	
Ranjana Khetrepal	MD	Professor,	Amritsar, Punjab, India
		Department of Anesthesia,	
		Government Medical College, Amritsar	
		Email – <u>rkhetarpal9@hotmail.com</u>	
Neeraj Sharma	MD	Professor,	Amritsar, Punjab, India
=	1		, and the second

		Department of Transfusion,	
		Government Medical College, Amritsar	
	1.55	Email – ankuramba@yahoo.co.in	
Neetu Kukar	MD	Department of Immunohematology and Blood	Faridkot, Punjab, India
		Transfusion,	
		Guru Gobind Singh Medical College and Hospital	
		Email - Neetukukar75@gmail.com	
Divya Kavita	MD	Department of Anesthesia,	Faridkot, Punjab, India
		Guru Gobind Singh Medical College and Hospital	
		Email - <u>Divya.kavita29@gmail.com</u>	
Rajesh Kumar	MD	Professor,	Ludhiana, Punjab, India
		Department of Immunohematology and Blood	
		Transfusion,	
		Dayanand Medical College and Hospital	
		Email - <u>Drkumarrajesh71@gmail.com</u>	
Rajesh Mahajan	MD	Professor,	Ludhiana, Punjab, India
		Department of Internal Medicine,	
		Dayanand Medical College and Hospital	
		Email - drrmahajan@gmail.com	
Gurpreet Singh	MD	Department of Respiratory Medicine, Satguru Partap	Ludhiana, Punjab, India
		Singh Hospitals,	
		Email - Singhgurpreet18@gmail.com	
Jaspreet Kaur	MD	Department of Microbiology,	Ludhiana, Punjab, India
		Satguru Partap Singh Hospitals,	
		Email – <u>drjaspreet18@gmail.com</u>	
Raminder Pal Singh	MD	Professor,	Patiala, Punjab, India
		Department of Internal Medicine,	
		Government Medical College, Patiala	
		Email – <u>Drsibial@yahoo.com</u>	
Rajni Bassi	MD	Department of Transfusion Medicine, Government	Patiala, Punjab, India
•		Medical College, Patiala	
		Email - rajniajata@yahoo.com	
Swapneil Parikh	DNB	Department of Infectious Diseases,	Mumbai, India
_		Kasturba Hospital	
		Email – <u>dr.swapneilparikh@gmail.com</u>	
Om Shrivastav	MD	Department of Infectious Diseases,	Mumbai, India
		Kasturba Hospital	
		Email – omshrivastav70@gmail.com	
Jayanthi Shastri	MD	Department of Microbiology,	Mumbai, India
•		Kasturba Hospital	,
		Email – <u>jsshastri@gmail.com</u>	
Maherra Desai	MA	Clinical Research Department,	Mumbai, India
		Kasturba Hospital	
		Email – maherrakhambaty@gmail.com	
Shreevatsa Udupa	MBBS	Clinical Research Department,	Mumbai, India
Since various e daspa	1,1225	Kasturba Hospital	17201110411, 111014
		Email – <u>drshreevatsaudupa@gmail.com</u>	
Varun A Bafna	DNB	Department of Medicine,	Kolhapur, Maharashtra,
	21.2	RCSM Government Medical College	India
		Email - drvarunbafna6@gmail.com	
Vijay Barge	MD	Department of Medicine,	Kolhapur, Maharashtra,
		RCSM Government Medical College	India
		Email – vijaybarge6766@gmail.com	
Rajendra Madane	MD	Department of Blood Bank,	Kolhapur, Maharashtra,
rajonora muanto	1.12	RCSM Government Medical College	India
		Reply Government Medical College	india

		Email - drrajmadane@gmail.com		
Sheetal Yadav	MD	Department of Medicine, RCSM Government Medical College Email – sheetaly23@gmail.com	Kolhapur, Maharashtra, India	
Sanjeev Mishra	MCh	Director, All India Institute of Medical Sciences, Jodhpur Email - misralko@gmail.com	Jodhpur, Rajasthan, India	
Archana Bajpayee	MD	Department of Transfusion Medicine, All India Institute of Medical Sciences, Jodhpur Email - drarchanabajpai@yahoo.co.in	Jodhpur, Rajasthan, India	
MK Garg	DM	Professor, Department of Internal Medicine, All India Institute of Medical Sciences, Jodhpur Email - mkgargs@gmail.com	Jodhpur, Rajasthan, India	
GK Bohra	MD	Department of Internal Medicine, All India Institute of Medical Sciences, Jodhpur Email - gopalbohra17@gmail.com	Jodhpur, Rajasthan, India	
Vijaylakshmi Nag	MD	Professor, Department of Microbiology, All India Institute of Medical Sciences, Jodhpur Email - nagy@aiimsjodhpur.edu.in	Jodhpur, Rajasthan, India	
Puneeth Babu Anne	MD	Department of Transfusion Medicine, All India Institute of Medical Sciences, Jodhpur Email - puneethbabuanne@gmail.com	Jodhpur, Rajasthan, India	
Mohd. Nadeem	MD	Department of Internal Medicine, All India Institute of Medical Sciences, Jodhpur Email - mohdnadeemmdmbbs@gmail.com	Jodhpur, Rajasthan, India	
Pallavi Singh	MBBS	Department of Transfusion Medicine, All India Institute of Medical Sciences, Jodhpur Email - pallavi90.ps@gmail.com	Jodhpur, Rajasthan, India	
Ram Niwas	MD	Department of Pulmonary Medicine, All India Institute of Medical Sciences, Jodhpur Email - drrniwas@gmail.com	Jodhpur, Rajasthan, India	
Niranjan S Khaire	MD	Department of Internal Medicine, Post Graduate Institute of Medical Education and Research Email – niranjankhaire@gmail.com	Chandigarh, India	
Professor Rattiram Sharma	MD	Professor, Department of Transfusion Medicine, Post Graduate Institute of Medical Education and Research Email – rrsdoc@hotmail.com	Chandigarh, India	
Professor Mini P Singh	MD	Professor, Department of Virology, Post Graduate Institute of Medical Education and Research Email – minipsingh@gmail.com	Chandigarh, India	
Naresh Sachdeva	PhD	Department of Endocrinology, Post Graduate Institute of Medical Education and Research Email – naresh sach@rediffmail.com	Chandigarh, India	
Suchet Sachdev	MD	Department of Transfusion Medicine, Post Graduate Institute of Medical Education and Research Email – suchet.sachdev@gmail.com	Chandigarh, India	

Rekha Hans	MD	Department of Transfusion Medicine,	Chandiga	ırh, India
		Post Graduate Institute of Medical Education and		,
		Research		
		Email - drhansrekha@gmail.com		
Vikas Suri	MD	Department of Internal Medicine,	Chandiga	rh. India
, 11ttl 5 5 411	1.12	Post Graduate Institute of Medical Education and	011111111111111111111111111111111111111	,
		Research		
		Email – surivikas9479@gmail.com		
Professor L N	MD	Professor,	Chandiga	rh India
Yaddanapudi	1,125	Department of Anesthesiology and Intensive Care,	Chanaige	iii, iiidid
1 wooding out		Post Graduate Institute of Medical Education and		
		Research		
		Email – Narayana.yaddanapudi@gmail.com		
PVM Lakshmi	MD	Professor,	Chandiga	rh India
1 VIVI Laksiiiii	MID	School of Public Health,	Chandige	iii, iiidia
		Post Graduate Institute of Medical Education and		
		Research		
		Email – pvm_lakshmi@yahoo.com		
Neha Singh	MD	Department of Transfusion Medicine,	Dotno Ri	har, India
Nella Siligii	MID	All India Institute of Medical Sciences, Patna	railla, Di	nai, muia
Divendu Bhushan	MD	Email - drnehasingh@aiimspatna.org	Dotno Di	har, India
Divelidu bilusilali	MID	Department of Internal Medicine,	Patila, Di	nar, muia
		All India Institute of Medical Sciences, Patna		
NT ' 17	MD	Email - divendb@gmail.com	D · D'	1 T 1'
Neeraj Kumar	MD	Department of Trauma and Emergency Medicine,	Patna, Bi	har, India
		All India Institute of Medical Sciences, Patna		
3.6 1'11 TD 1	100	Email - drneerajk@aiimspatna.org	D	361 1.
Muralidhar Tambe	MD	Professor,	Pune,	Maharashtra,
		Department of Community Medicine	India	
		Byramjee Jeejeebhoy Medical College, Pune		
		Email – <u>muralidhartambe@gmail.com</u>		
Sonali Salvi	MD	Department of Internal Medicine	Pune,	Maharashtra,
		Byramjee Jeejeebhoy Medical College, Pune	India	
		Email – sonalionly@gmail.com		
Nalini Kadgi	MD	Department of Pathology	Pune,	Maharashtra,
		Byramjee Jeejeebhoy Medical College, Pune	India	
		Email – Nalini.kadgi@gmail.com		
Shashikala Sangle	MD	Professor,	Pune,	Maharashtra,
		Department of Internal Medicine	India	
		Byramjee Jeejeebhoy Medical College, Pune		
		Email – shashisangle@yahoo.com		
Leena Nakate	MD	Professor,	Pune,	Maharashtra,
		Department of Pathology	India	
		Byramjee Jeejeebhoy Medical College, Pune		
		Email – <u>leena8365@gmail.com</u>		
Samir Joshi	MS	Professor,	Pune,	Maharashtra,
		Department of ENT	India	
		Byramjee Jeejeebhoy Medical College, Pune		
		Email – <u>drsamirjoshi2012@gmail.com</u>		
Rajesh Karyakarte	MD	Professor,	Pune,	Maharashtra,
- -		Department of Microbiology	India	,
		Byramjee Jeejeebhoy Medical College, Pune		
		Diamijee recjection integral contege, I am		
		Email – karyakarte@hotmail.com		
Suraj Goyanka	DM		Pune,	Maharashtra,

		Email – surajgoyanka@gmail.com		
Nimisha Sharma	MD	Department of Immunohematology and blood transfusion, ESIC Medical College and Hospital	Faridabad, India	Haryana,
Nikhil Verma	MD	Email - Nims427@gmail.com Department of Internal Medicine, ESIC Medical College and Hospital Email - Drnick.ver@gmail.com	Faridabad, India	Haryana,
Asim Das	MD	Dean, ESIC Medical College and Hospital Email - Dean-faridabad@esic.nic.in	Faridabad, India	Haryana,
Monika Bahl	MBA	Clinical Development Services Agency, Translational Health Sciences and Technology Institute Email - Monikabahl.cdsa@thsti.res.in	Faridabad, India	Haryana,
Nitya Wadhwa	MD	Clinical Development Services Agency, Translational Health Sciences and Technology Institute Email - Nitya.wadhwa@thsti.res.in	Faridabad, India	Haryana,
Shreepad Bhat	MD	Professor, Department of Internal Medicine, Smt. Kashi Bai Navale Medical College Email - Smb.med@gmail.com	Pune, India	Maharashtra,
Shweta Deshmukh	DNB	Department of Internal Medicine, Smt. Kashi Bai Navale Medical College Email - Shwetas602@gmail.com	Pune, India	Maharashtra,
Vrushali Wagh	MD	Department of Internal Medicine, Smt. Kashi Bai Navale Medical College Email - drvrushaliwagh@gmail.com	Pune, India	Maharashtra,
Atul Kulkarni	DCP	Department of Blood Bank, Jankalyan Blood bank Email - Director.jkbb@gmail.com	Pune, India	Maharashtra,
Tanvi Yardi	DCP	Department of Blood Bank, Jankalyan Blood bank Email - ytanvi@rediffmail.com	Pune, India	Maharashtra,
Ram S Kaulgud	MD	Department of Internal Medicine, Karnataka Institute of Medical Sciences Email – drkaulgud.kims@gmail.com	Hubballi, India	Karnataka,
Purushottam Reddy	MD	Professor, Department of Pathology, Karnataka Institute of Medical Sciences Email – reddy puru24@rediffmail.com	Hubballi, India	Karnataka,
Kavitha Yevoor	MD	Department of Pathology Karnataka Institute of Medical Sciences Email – kavithayevoor@gmail.com	Hubballi, India	Karnataka,
Prashanth Gajula	MD	Department of Medicine Karnataka Institute of Medical Sciences Email – prashanthgajula3333@gmail.com	Hubballi, India	Karnataka,
Vivek Maleyur	MD	Department of Medicine Karnataka Institute of Medical Sciences Email – vivekmaleyur@gmail.com	Hubballi, India	Karnataka,
Medini S	MD	Department of Medicine Karnataka Institute of Medical Sciences Email – medinipuranik@gmail.com	Hubballi, India	Karnataka,
Mohith HN	MD	Department of Medicine,	Hubballi,	Karnataka,

		Karnataka Institute of Medical Sciences	India
Anil Gurtoo	MD	Email – mohithhn@gmail.com	Nam Dallai India
Ann Gurtoo	MD	Professor,	New Delhi, India
		Department of Internal Medicine, Lady Hardinge Medical College	
		Email - Anilgurtoo2@gmail.com	
Ritika Sud	MD		Non Dallei India
Kitika Sud	MD	Department of Internal Medicine,	New Delhi, India
		Lady Hardinge Medical College	
Cananata Dalania	MD	Email - <u>Sud.ritika@gmail.com</u>	Non Dallei India
Sangeeta Pahuja	MD	Department of Transfusion Medicine,	New Delhi, India
		Lady Hardinge Medical College Email - Sangeeta.pahuja.s@gmail.com	
A Dualia ale	MD		Non Dallei India
Anupam Prakash	MD	Professor, Department of Internal Medicine,	New Delhi, India
		Lady Hardinge Medical College	
D '' - C '	100	Email - prakashanupam@hotmail.com	N. D. H. I. I.
Parijat Gogoi	MD	Department of Biochemistry,	New Delhi, India
		Lady Hardinge Medical College	
G1 '1' G1 11	100	Email - parijatgogoi@rediffmail.com	N. D. H. I. I.
Shailja Shukla	MD	Department of Pathology,	New Delhi, India
		Lady Hardinge Medical College	
	3.55	Email - shailjashukla@gmail.com	
D Himanshu Reddy	MD	Department of Internal Medicine,	Lucknow, Uttar
		King George's Medical University,	Pradesh, India
		Email - dr.himanshu.reddy@gmail.com	
Chandra Tulika	MD	Professor,	Lucknow, Uttar
		Department of Transfusion Medicine,	Pradesh, India
		King George's Medical University,	
		Email - <u>drtulikachandra@gmail.com</u>	
Saurabh Pandey	MD	Department of Internal Medicine,	Lucknow, Uttar
		King George's Medical University	Pradesh, India
		Email - saurabhp2013@gmail.com	
Pradeep Maurya	MBBS	Department of Internal Medicine,	Lucknow, Uttar
		King George's Medical University	Pradesh, India
		Email – <u>pkm4477@gmail.com</u>	
Ali Wahid	PhD	Department of Pathology and Biochemistry,	Lucknow, Uttar
		King George's Medical University	Pradesh, India
		Email – <u>aliwahid78@gmail.com</u>	
Vivek Kumar	MD	Department of Internal Medicine,	Lucknow, Uttar
		King George's Medical University	Pradesh, India
		Email – <u>iamvivekbhagat@gmail.com</u>	
Kamlesh Upadhyay	MD	Professor,	Ahmedabad, Gujarat,
		Department of Internal Medicine,	India
		Byramjee Jeejeebhoy Medical College, Ahmedabad	
		Email - <u>drkjupadhyay@hotmail.com</u>	
Nidhi Bhatnagar	MD	Department of Transfusion Medicine, Byramjee	Ahmedabad, Gujarat,
		Jeejeebhoy Medical College, Ahmedabad	India
		Email - <u>bhatnagarnidhi@ymail.com</u>	
Nilima Shah	MD	Department of Internal Medicine,	Ahmedabad, Gujarat,
		Byramjee Jeejeebhoy Medical College, Ahmedabad	India
		Email – <u>drnilimashah@gmail.com</u>	
Mamta Shah	MD	Department of Transfusion Medicine, Byramjee	Ahmedabad, Gujarat,
		Jeejeebhoy Medical College, Ahmedabad	India
		Email - mamtacshah@gmail.com	
Tarak Patel	MD	Department of Transfusion Medicine, Byramjee	Ahmedabad, Gujarat,
		Jeejeebhoy Medical College, Ahmedabad	India

		Email - drtarakp@yahoo.com		
Ram Mohan Jaiswal	MD	Professor, Blood Center & Transplant Immunology Lab, Mahatma Gandhi University of Medical Sciences and Technology Email - drrmjaiswal@mgumst.org	Jaipur, Rajasthan, India	
Ashish Jain	MD	Department of Respiratory Medicine, Mahatma Gandhi University of Medical Sciences and Technology Email – drjainashish79@gmail.com	Jaipur, Rajasthan, India	
Shweta Sharma	MD	Department of Pathology, Mahatma Gandhi University of Medical Sciences and Technology Email – drshwetasharma@mgmust.org	Jaipur, Rajasthan, India	
Puneet Rijhwani	MD	Department of Internal Medicine, Mahatma Gandhi University of Medical Sciences and Technology Email - puneet284@rediffmail.com	Jaipur, Rajasthan, India	
Naveen Gupta	DM	Department of Clinical Hematology, Mahatma Gandhi University of Medical Sciences and Technology Email – drnaveengupta 1988@gmail.com	Jaipur, Rajasthan, India	
Tinkal C Patel	MD	Professor Department of Internal Medicine, Government Medical College, Surat Email: pateltinkal@yahoo.com	Surat, Gujarat, India	
Mahesh G Solu	MD	Department of Internal Medicine, Government Medical College, Surat Email - drmaheshgsolu@yahoo.in	Surat, Gujarat, India	
Jitendra Patel	MD	Department of Immunology and Blood Transfusion, Government Medical College, Surat Email: onlyg2@gmail.com	Surat, Gujarat, India	
Yash R Shah	Medical Student	Department of Internal Medicine, Government Medical College, Surat Email: yashu211996@gmail.com	Surat, Gujarat, India	
Mayur Jarag	MD	Professor, Department of Immunology and Blood Transfusion, Government Medical College, Surat Email: drmayurjarag@gmail.com	Surat, Gujarat, India	
Varsha Godbole	MD	Professor, Department of Internal Medicine, GMERS Medical College and Hospital, Gotri Email – drvgodbole@gmail.com	Vadodara, Gujarat, India	
Meenakshi Shah	MD	Department of Internal Medicine, GMERS Medical College and Hospital, Gotri Email – drmeenakshi20@yahoo.com	Vadodara, Gujarat, India	
Rikin Raj	MD	Department of Medicine, GMERS Medical College and Hospital, Gotri Email - Rikin.raj@gmail.com	Vadodara, Gujarat, India	
Irfan Nagori	MD	Department of Medicine, GMERS Medical College and Hospital, Gotri Email - Irfizz@gmail.com	Vadodara, Gujarat, India	
Pramod R Jha	MD	Professor, Department of Internal Medicine, Sumandeep Vidyapeeth and Dhiraj Hospital	Vadodara, Gujarat, India	

		Email - <u>Dr.pkrnj@gmail.com</u>		
Arti D Shah	DNB	Professor,	Vadodara,	Gujarat,
		Department of Respiratory Medicine, Sumandeep	India	
		Vidyapeeth and Dhiraj Hospital		
		Email - Artidhawal76@gmail.com		
Gowtham Yeeli	MBBS	Department of Internal Medicine, Sumandeep	Vadodara,	Gujarat,
		Vidyapeeth and Dhiraj Hospital	India	J,
		Email - yeeligautham@gmail.com	1110111	
Archit Jain	MBBS	Department of Internal Medicine, Sumandeep	Vadodara,	Gujarat,
Tuemt Jam	MDDS	Vidyapeeth and Dhiraj Hospital	India	oujarat,
		Email - Jain.archit2004@gmail.com	Illuia	
Rooppreet Kaur Gill	MBBS	Department of Internal Medicine, Sumandeep	Vadodara,	Gujarat,
Rooppieet Rauf Gill	WIDDS	Vidyapeeth and Dhiraj Hospital	India	Jujarai,
		Email – dr.roopgill@outlook.com	Illuia	
KV Sreedhar Babu	MD		TIDLIDATI AN	IDIIDA
K v Sreednar Babu	MD	Professor,	TIRUPATI, AN	
		Department of Transfusion Medicine,	PRADESH, India	1
		Sri Venkateswra Institute of Medical Sciences		
	3.55	Email - kinneravsb@gmail.com		
B Suresh Babu	MD	Department of Transfusion Medicine,	TIRUPATI, AN	
		Sri Venkateswra Institute of Medical Sciences	PRADESH, India	a
		Email - <u>dr.suresh02@gmail.com</u>		
Alladi Mohan	MD	Department of Internal Medicine,	TIRUPATI, AN	
		Sri Venkateswra Institute of Medical Sciences	PRADESH, India	a
		Email - alladimohan2@gmail.com		
B Vengamma	DM	Professor,	TIRUPATI, AN	IDHRA
_		Department of Neurology,	PRADESH, India	a
		Sri Venkateswra Institute of Medical Sciences	,	
		Email - bhumavengamma@gmail.com		
K Chandra Sekhar	MD	Department of Internal Medicine,	TIRUPATI, AN	IDHRA
		Sri Venkateswra Institute of Medical Sciences	PRADESH, India	
		Email - chandu24kondaa@gmail.com		-
Srinivasulu Damam	MD	Department of Internal Medicine,	Kurnool,	Andhra
Similaria Damani	WIE	Kurnool Medical College	Pradesh, India	mama
		Email – damamsrinivas@gmail.com	Tradesii, maia	
K Narsimhulu	MD	Professor,	Kurnool,	Andhra
Karsiiiitutu	IVID	Department of Internal Medicine,	Pradesh, India	Anuma
		Kurnool Medical College	Traucsii, muia	
		Email – nara17kg@gmail.com		
CAnana	MD		171	A11
C Aparna	MD	Professor,		Andhra
		Department of Pathology,	Pradesh, India	
		Kurnool Medical College		
<u> </u>	1.00	Email – achinnam893@gmail.com	77 1	
G Baleswari	MD	Professor,	·	Andhra
		Department of Pathology,	Pradesh, India	
		Kurnool Medical College		
		Email – eswarigolla@gmail.com		
Ravindranath Reddy K	MBBS	Department of Internal Medicine,	·	Andhra
		Kurnool Medical College	Pradesh, India	
		Email –		
		ravindranathreddy.kaipa@gmail.com		
P Chandrasekhar	DM	Professor,	Kurnool,	Andhra
			A. Contract of the Contract of	
		Department of Cardiology,	Pradesh, India	
		Department of Cardiology, Kurnool Medical College	Pradesh, India	
			Pradesh, India	

Panjwani		Medical College, Bhavnagar Email - Spanjwani0@gmail.com	India
Pankaj J. Akholkar	MD	Department of Internal Medicine, Government Medical College, Bhavnagar Email - Drpankaj md@yahoo.com	Bhavnagar, Gujarat, India
Kairavi Parthesh Joshi	MD	Department of Microbiology, Government Medical College, Bhavnagar Email - drkairavi@yahoo.in	Bhavnagar, Gujarat, India
Pragnesh H. Shah	MD	Department of Microbiology, Government Medical College, Bhavnagar Email - Drphshah73@yahoo.com	Bhavnagar, Gujarat, India
Manish Barvaliya	MD	Department of Internal Medicine, Government Medical College, Bhavnagar Email - drmanishbarvaliya@gmail.com	Bhavnagar, Gujarat, India
Milind Baldi	DM	Department of Respiratory Medicine, Mahatma Gandhi Memorial Medical College, Email – milindbaldi@gmail.com	Indore, Madhya Pradesh, India
Ashok Yadav	MD	Department of Transfusion Medicine, Mahatma Gandhi Memorial Medical College, Email – drashokmyh@gmail.com	Indore, Madhya Pradesh, India
Manoj Gupta	DM	Department of Internal Medicine, Mahatma Gandhi Memorial Medical College, Email – drmanojgupta24@gmail.com	Indore, Madhya Pradesh, India
Nitin Rawat	MD	Department of Internal Medicine, Mahatma Gandhi Memorial Medical College, Email – drnitin.rawat@gmail.com	Indore, Madhya Pradesh, India
Dilip Chawda	MD	Department of Respiratory Medicine, Mahatma Gandhi Memorial Medical College, Email – drdilipchawda@gmail.com	Indore, Madhya Pradesh, India
M Natarajan	MD	Professor, Department of Internal Medicine, Madurai Medical College Email - laknatraj@gmail.com	Madurai, Tamil Nadu, India
M Sintha	MD	Department of Immunohematology and Blood Transfusion, Madurai Medical College, Email - Drsinthathirumalai81@gmail.com	Madurai, Tamil Nadu, India
David Pradeep Kumar	MD	Professor, Department of Internal Medicine, Madurai Medical College Email - pradeepkdavid@hotmail.com	Madurai, Tamil Nadu, India
Fathhur Rabbani	MBBS	Department of Internal Medicine, Madurai Medical College Email - Rfathhur3893@gmail.com	Madurai, Tamil Nadu, India
Vrushali Khirid Khadke	DNB	Department of Interventional Pulmonology, Poona Hospital and Research Center, Email – vgkhadke@gmail.com	Pune, Maharashtra, India
Dattatray Patki	DNB	Department of Internal Medicine, Poona Hospital and Research Center, Email – dattatraypatki@gmail.com	Pune, Maharashtra, India
Sonali Marathe	MD	Department of Pathology and Transfusion Medicine, Poona Hospital and Research Center, Email – drmarathe.sonali@gmail.com	Pune, Maharashtra, India
Clyde D'Souza	MPH	Department of Internal Medicine, Poona Hospital and Research Center,	Pune, Maharashtra, India

		Email – <u>clyde822@gmail.com</u>	
Vipul Tadha	MBBS	Department of General Medicine, Poona Hospital and Research Center, Email – vipultadham6@gmail.com	Pune, Maharashtra, India
Satyam Arora	MD	Department of Transfusion Medicine, Super Specialty Paediatric Hospital and Post Graduate Teaching Institute Email - satyamarora83@gmail.com	Noida, Uttar Pradesh, India
Devendra Kumar Gupta	MCh	Professor, Department of Paediatric Surgery, Super Specialty Paediatric Hospital and Post Graduate Teaching Institute Email - profdkgupta@gmail.com	Noida, Uttar Pradesh, India
Seema Dua	MD	Department of Transfusion Medicine, Super Specialty Paediatric Hospital and Post Graduate Teaching Institute Email - seemadua06@gmail.com	Noida, Uttar Pradesh, India
Nitu Chauhan	MD	Department of Transfusion Medicine, Sarojini Naidu Medical College Email - drnituchauhan26@gmail.com	Agra, Uttar Pradesh, India
Ajeet Singh Chahar	MD	Department of Internal Medicine, Sarojini Naidu Medical College Email - ajeet_doctor@yahoo.co.in	Agra, Uttar Pradesh, India
Joy John Mammen	MD	Professor, Department Transfusion Medicine, Christian Medical College Email - joymammen@cmcvellore.ac.in	Vellore, Tamil Nadu, India
Snehil Kumar	MD	Department Transfusion Medicine, Christian Medical College Email - snehilsimulation25@gmail.com	Vellore, Tamil Nadu, India
Dolly Daniel	MD	Professor, Department Transfusion Medicine, Christian Medical College Email - dollyd@cmcvellore.ac.in	Vellore, Tamil Nadu, India
Ravindraa Singh	MD	Department of Transfusion Medicine, Aditya Birla Memorial Hospital Email – rpsingh008@gmail.com	Pune, Maharashtra, India
Venkatesh Dhat	MD	Department of Critical Care Medicine, Aditya Birla Memorial Hospital Email – drvenkateshdhat@yahoo.co.in	Pune, Maharashtra, India
Yogesh Agarwal	MD	Department of Pulmonary Medicine, Aditya Birla Memorial Hospital Email – dryogesh1980@gmail.com	Pune, Maharashtra, India
Sohini Arora	MD	Department of Laboratory Medicine, Aditya Birla Memorial Hospital Email – sohini.arora@adityabirla.com	Pune, Maharashtra, India
Ashish Pathak	PhD	Professor, Department of Paediatrics, RD Gardi Medical College Email - drashish.jpathak@gmail.com	Ujjain, Madhya Pradesh, India
Manju Purohit	MD	Department of Pathology, RD Gardi Medical College Email – manjuraj.purohit64@gmail.com	Ujjain, Madhya Pradesh, India
Ashish Sharma	MD	Department of Medicine, RD Gardi Medical College	Ujjain, Madhya Pradesh, India

		F '1 1' 1 ' 1 @ 1 '		
Jayashree Sharma	MD	Email – ashishricha@yahoo.co.in Professor, Department Transfusion Medicine, Seth GS Medical College and KEM Hospital Email – jayashreesharma@kem.edu	Parel, Mumbai, Maharashtra, India	
Manisha Madkaikar	MD	Scientist G, Indian Council of Medical Research - National Institute of Immunohaematology Email - madkaikarmanisha@gmail.com	Parel, Mumbai, Maharashtra, India	
Kavita Joshi	MD	Department Internal Medicine, Seth GS Medical College and KEM Hospital Email – kavitajoshi@kem.edu	Parel, Mumbai, Maharashtra, India	
Reetika Malik Yadav	MBBS	Scientist B, Indian Council of Medical Research - National Institute of Immunohaematology Email - reetikamalik@gmail.com	Parel, Mumbai, Maharashtra, India	
Swarupa Bhagwat	MD	Department of Transfusion Medicine, Seth GS Medical College and KEM Hospital Email - swarupabhagwat@kem.edu	Parel, Mumbai, Maharashtra, India	
Niteen D Karnik	MD	Professor, Department of Internal Medicine, Lokmanya Tilak Municipal Medical College & General Hospital Email - niteenkarnik@gmail.com	Mumbai, Maharashtra, India	
Yojana A Gokhale	MD	Professor, Department of Internal Medicine, Lokmanya Tilak Municipal Medical College & General Hospital Email - Yojana1962@gmail.com	Mumbai, Maharashtra, India	
Leena Naik	MD	Professor, Department of Pathology, Lokmanya Tilak Municipal Medical College & Geenral Hospital Email - Leena_pnaik@yahoo.co.in	Mumbai, Maharashtra, India	
Sangita Margam	MD	Department of Pathology, Lokmanya Tilak Municipal Medical College & General Hospital Email - drsvgoyal@gmail.com	Mumbai, Maharashtra, India	
Santasabuj Das	MD	Scientist F, Division of Clinical Medicine, National Institute of Cholera and Enteric Diseases – Indian Council of Medical Research, Kolkata Email - dasss@icmr.org.in	Kolkata, West Bengal, India	
Dr Alka Turuk	MD	Scientist C, Division of Epidemiology and Communicable Division, Indian Council of Medical Research alka.turukicmr@gmail.com	New Delhi, India	
V Saravana Kumar	PhD	Scientist B, Epidemiology and Biostatistics Division, Indian Council of Medical Research - National Institute of Epidemiology Email - saravanan.biostat1985@gmail.com	Chennai, Tamil, India	
K Kanagasabai	MSc	Principal Technical Officer Computing and Informatics Science Division,	Chennai, Tamil, India	

		Indian Council of Medical Research - National Institute of Epidemiology Email - sabaiicmr@hotmail.com		
R Sabarinathan	BE	Scientist C, Project Division, Indian Council of Medical Research - National Institute of Epidemiology Email - sabari193@gmail.com	Chennai	, Tamil, India
Gururaj Deshpande	PhD	Scientist B, Diagnostic Virology Group, Indian Council of Medical Research – National Institute Virology, Pune Email - gndeshpande@gmail.com	Pune, India	Maharashtra,
Sharda Sharma	PhD	Scientist B, Diagnostic Virology Group, Indian Council of Medical Research – National Institute Virology, Pune Email - sharma.h.sharada@gmail.com	Pune, India	Maharashtra,
Rashmi Gunjikar	MSc	Senior Technical Officer, Diagnostic Virology Group, Indian Council of Medical Research – National Institute Virology, Pune Email - rgunjikar@gmail.com	Pune, India	Maharashtra,
Anita Shete	PhD	Scientist D, Maximum Containment Laboratory, Indian Council of Medical Research – National Institute Virology, Pune Email - anitaaich2008@gmail.com	Pune, India	Maharashtra,
Darpan Phagiwala	BSc	Technician 3, Diagnostic Virology Group, Indian Council of Medical Research – National Institute Virology, Pune Email - darpan.phag@gmail.com	Pune, India	Maharashtra,
Chetan Patil	BSc	Technician 3, Diagnostic Virology Group, Indian Council of Medical Research – National Institute Virology, Pune Email - chetanpatilniv@gmail.com	Pune, India	Maharashtra,
Snehal Shingade	MSc	Technical Assistant, Diagnostic Virology Group, Indian Council of Medical Research – National Institute Virology, Pune Email - shingadesnehal1@gmail.com	Pune, India	Maharashtra,
Kajal Jarande	MSc	Technician 3, Diagnostic Virology Group, Indian Council of Medical Research – National Institute Virology, Pune Email - kajaljarande919@gmail.com	Pune, India	Maharashtra,
Himanshu Kaushal	PhD	Scientist B, Human Influenza Group, Indian Council of Medical Research – National Institute Virology, Pune Email - hkarya@gmail.com	Pune, India	Maharashtra,
Pragya D Yadav	PhD	Scientist E, Maximum Containment Laboratory,	Pune, India	Maharashtra,

		Indian Council of Medical Research - National		
		Institute Virology, Pune		
		Email - hellopragya22@gmail.com		
Gajanan Sapkal	PhD	Scientist E,	Pune,	Maharashtra,
		Diagnostic Virology Group, Indian Council of	India	
		Medical Research – National Institute Virology, Pune		
		Email - gajanansapkalniv@gmail.com		
Priya Abraham	PhD	Professor,	Pune,	Maharashtra,
		Director, Indian Council of Medical Research -	India	
		National Institute Virology, Pune		
		Email - director.niv@icmr.gov.in		

Abstract

Objectives: Convalescent plasma (CP) as a passive source of neutralizing antibodies and immunomodulators is a century-old therapeutic option used for the management of viral diseases. We investigated its effectiveness for the treatment of COVID-19.

Design: Open-label, parallel-arm, phase II, multicentre, randomized controlled trial.

Setting: Thirty-nine public and private hospitals across India.

Participants: Hospitalized, moderately ill confirmed COVID-19 patients (PaO2/FiO2: 200-300 or respiratory rate $> 24/\min$ and SpO2 $\le 93\%$ on room air).

Intervention: Participants were randomized to either control (best standard of care (BSC)) or intervention (CP + BSC) arm. Two doses of 200 mL CP was transfused 24 hours apart in the intervention arm.

Main Outcome Measure: Composite of progression to severe disease (PaO2/FiO2<100) or all-cause mortality at 28 days post-enrolment.

Results: Between 22nd April to 14th July 2020, 464 participants were enrolled; 235 and 229 in intervention and control arm, respectively. Composite primary outcome was achieved in 44 (18.7%) participants in the intervention arm and 41 (17.9%) in the control arm [aOR: 1.09; 95% CI: 0.67, 1.77]. Mortality was documented in 34 (14.5%) and 31 (13.5%) participants in intervention and control arm, respectively [aOR) 1.06 95% CI: 0.61 to 1.83].

Interpretation: CP was not associated with reduction in mortality or progression to severe COVID-19. This trial has high generalizability and approximates real-life setting of CP therapy in settings with limited laboratory capacity. A priori measurement of neutralizing antibody titres in donors and participants may further clarify the role of CP in management of COVID-19.

Trial registration: The trial was registered with Clinical Trial Registry of India (CTRI); CTRI/2020/04/024775.

Introduction

With few specific therapeutic options available to manage infection with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), the novel coronavirus disease (COVID-19) presents a unique set of challenges for healthcare providers globally. In addition to non-pharmacological interventions, health systems have responded by devising strategies to manage COVID-19 using repurposed medications and revisiting older strategies, such as using convalescent plasma (CP). CP is a passive immunization strategy which has been used on several occasions in the past century, inspiring clinical expectations that it could emerge as a potential therapy for a disease with no proven, effective interventions.¹

CP is a source of anti-viral neutralizing antibodies (NAb). Other immune pathways such as antibody-dependent cellular cytotoxicity, complement activation, or phagocytosis are putative mechanisms through which CP may exert its therapeutic effect in COVID-19 patients.² Additionally, anti-inflammatory cytokines, defensins, pentraxins and other immunomodulatory proteins may have a role in alleviating systemic inflammatory response syndrome, the main pathophysiological basis for acute respiratory distress syndrome (ARDS) and mortality from COVID-19 pneumonia.² Historically, CP has been used in viral diseases such as poliomyelitis, measles, mumps and influenza in the pre-vaccine era and more recently, during the Influenza, Ebola, and SARS coronavirus epidemics with varying degrees of success.^{3–5} A recent systematic review on the use of CP in non-COVID-19 severe respiratory viral infections found no mortality benefit.⁶ There is evidence that CP collected from COVID-19 survivors contains Receptor Binding Domain specific antibodies with potent antiviral activity.⁷ However, effective titres of NAb, optimal timing for CP therapy, optimal timing for plasma donation, and the severity class of patients who are likely to benefit from CP therapy remains unclear.

Since the publication of the first case series from China, multiple observational studies have been published, some on pre-print servers, highlighting the usefulness of CP in reducing mortality, hospital stay and viral load in COVID-19 patients.⁸⁻¹² Only two randomized controlled trials on CP use in COVID-19 have been published, one from China and the other from the Netherlands. 13,14 Both were halted prematurely, the China study due to inadequate patient enrolment and the one from the Netherlands due to a need to redesign the trial based on interim findings. In both studies, no mortality benefit was noted, and the Dutch study raised uncertainties regarding pre-transfusion antibody-status of patients as a potential factor in identifying appropriate candidates for CP therapy. 14 This uncertainty in the published evidence is reflected in a recent systematic review, which remained undecided on both the safety and effectiveness of CP as a therapeutic option in hospitalized patients of COVID-19. 15 Meanwhile, CP therapy has received regulatory approval for use in patients in different countries. This has resulted in its widespread adoption in real-world clinical practice, where it is being used to treat COVID-19 patients with a wide spectrum of disease severity. 16,17 Given these uncertainties, we undertook the current study to determine the effectiveness of using CP in moderately ill COVID-19 patients admitted to hospitals across India in limiting progression to severe disease and determine the associated short-term adverse effects.

Methods

Study Design

The PLACID trial was an open-label, parallel-arm, phase II, multicentre, randomized, controlled trial conducted in 39 tertiary care hospitals across India. Of these, 29 were teaching public hospitals and 10 were private hospitals spread across 14 States and Union Territories representing 25 cities.

Ethical approval was obtained from the ICMR Central Ethics Committee on Human Research (CECHR-002/2020) as well as from the Institutional Review Boards /Institutional Ethics Committees of all the participating hospitals. The lead author affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned have been explained. Patient or the public were not involved in the design, conduct, reporting or dissemination plans of our research. The study results will be disseminated to the study via their treating physicians. The study protocol can be accessed at: <a href="https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=NTk2NQ=="https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=NTk2NQ=="https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=NTk2NQ==

Participants

Patients aged at least 18 years who were confirmed to have COVID-19 based on a positive SARS-CoV-2 RT-PCR test and were admitted to the participating hospitals were screened for eligibility and included if they were moderately ill with either partial pressure of oxygen in arterial blood/fraction of inspired oxygen (PaO2/FiO2) ratio between 200-300 or respiratory rate >24/min with SpO2 \leq 93% on room air, ¹⁷ and if matched donor CP was available at the point of enrolment. Pregnant and lactating women, patients with known hypersensitivity to blood products, recipients of immunoglobulin in the last 30 days, patients with conditions precluding infusion of blood products, participants in any other clinical trials and critically ill patients with PaO2/ FiO2 < 200 or shock (requiring vasopressors to maintain a mean arterial pressure (MAP) >= 65 or MAP < 65) were considered ineligible to participate.

Eligible donors were either males or nulliparous females aged between 18-65 years, weighing over 50 kg, who had received a diagnosis of COVID-19 confirmed with a positive RT-PCR test, suffered from symptomatic COVID-19 with at least fever and cough, which had completely resolved for a period of 28 consecutive days prior to donation or a period of 14 days prior to donation with two negative SARS-CoV-2 RT-PCR tests from nasopharyngeal swabs collected 24 hours apart. All routine screening tests including ABO blood grouping, Rh phenotype, complete blood counts, screening for HIV, HBV, HCV, syphilis, malaria and total serum protein were conducted as per the Drugs and Cosmetics (Second Amendment) Rules, 2020.¹⁸

All participants or their family members or legally authorized representatives were provided with information regarding the trial in a language they were comfortable in, and written informed consent was obtained prior to participant recruitment.

Randomization and Masking

The randomization sequence was generated using the RALLOC module in STATA v.14 (College Station, Texas, USA) by an independent biostatistician from the Indian Council Medical Research-National Institute of Epidemiology (ICMR-NIE), Chennai, India. A stratified

block randomization strategy was used to allocate participants in a 1:1 ratio to receive either CP with the best standard of care (BSC) (intervention arm) or BSC alone (control arm). Stratification was done by sites; block randomization was done with unequal block sizes. After obtaining written, informed consent from an eligible patient, the site investigators screened the participant for recruitment, and called a member of the central trial coordinating team to receive the randomization sequence, ensuring concealment of allocation.

Procedures

Patients enrolled in the control arm received BSC for COVID-19 in keeping with the institutional protocol, which was dictated by the best available evidence at the time and guidelines for the management of COVID-19 issued by the government health authorities. The range of treatment protocols practised by the participating clinical sites for the management of COVID-19 patients included: antivirals (Hydroxychloroquine, Remdesivir, Lopinavir/Ritonavir, Oseltamivir), broad-spectrum antibiotics, immunomodulators (steroids, Tocilizumab) and supportive management (oxygen via nasal cannula, face mask, non-rebreathing face mask; non-invasive or invasive mechanical ventilation; awake proning). The decision to transfer to the intensive care unit (ICU) was dependent on the policies of the individual trial sites.

The intervention arm received two doses of 200 mL of CP, transfused 24 hours apart, in addition to the BSC. The two plasma units were collected preferably from different donors depending on the availability and ABO compatibility to increase chances of receiving CP with NAb. ¹⁹ If two different donors were not available, both the units were collected from a single donor. CP was collected from recovered COVID-19 patients by centrifugal separation using the apheresis equipment available at the facility after obtaining written informed consent from the donors. At least 20 mL of the donated plasma was stored at -80°C for measurement of SARS-CoV-2 NAb titres, as reliable and approved qualitative and quantitative tests were not available at the time of initiation of the study. Commercial qualitative immunoassays for SARS-CoV-2 antibodies on chemiluminescent immunoassay or enzyme-linked immunosorbent assay platforms approved by the ICMR became available halfway through the trial. Once available, sites were encouraged to use them before collection of CP.

All enrolled participants underwent clinical examination and a range of laboratory investigations including arterial blood gas (ABG) analysis, complete blood count, renal and hepatic function tests, and a coagulation profile on the day of enrolment (Day 0), and subsequently on days 1, 3, 5, 7 and 14. Chest imaging and biomarkers including serum ferritin, Lactate Dehydrogenase (LDH), C-reactive protein (CRP), and D-Dimer were obtained on days 0, 3 and 7. Serum for antibody titre assays was collected on days 0, 3 and 7; these samples were stored -80°C till further analysis at ICMR-National Institute of Virology (NIV), Pune, India. SARS-CoV-2 RT-PCR from nasopharyngeal swabs was repeated on days 3 and 7. All patients were contacted telephonically on day 28 to assess their health status.

Micro-neutralization test for SARS-CoV-2 was performed for determining the NAb titres in stored donor CP and participant serum from day 0, 3 and 7, at the Biosafety Level-3 facility at ICMR-NIV, Pune following standardized methods. Vero CCL-81-adapted SARS-CoV-2 (strain NIV2020770) isolated at ICMR-NIV, Pune. The detection range of NAb titers was 1:20 to

1:1280. Values reported as <1:20 was considered as undetectable NAb titers; values reported as >1:1280 was considered as 1:1280 for analysis.

Outcomes

The primary outcome of the study was a composite measure of progress to severe disease (PaO2/FiO2 ratio <100) any time within 28 days of enrolment or all-cause mortality at 28 days. Primary outcome was considered as "good" if the progress to severe disease or all-cause mortality could be prevented in the 28 days post enrolment and "poor" if not.

The secondary outcomes were clinical improvement and symptom resolution on day 7; variation in fraction of inspired oxygen (Fio2%) on days 1, 3, 5, 7 and 14; total duration of respiratory support during hospitalization and post enrolment duration of respiratory support till day 28 or discharge whichever is earlier; negative conversion of SARS-CoV-2 viral RNA on days 3 and 7; levels of biomarkers on days 3 and 7 post enrolment compared to baseline; requirement of vasopressor support; and clinical improvement on WHO ordinal scale on day 0,1,3,5,7,14 and 28 days. ²²The WHO ordinal scale was not mentioned in the initial study protocol but was added midway through the trial as it was felt that it will be a key endpoint in any future meta-analysis.

Safety outcomes were frequency of minor and serious adverse event (death and invasive mechanical ventilation, hemodynamic instability) within 6 hours of CP transfusion. Relatedness of a serious adverse event with the trial was assessed as per the definitions given by Edwards and Aronson.²³

Statistical Analysis

Assuming that 18% of the intervention arm would meet the composite primary outcome under the null hypothesis and 9% under the alternative hypothesis, for power of 80% and significance level of 5%, the sample size was calculated to be 226 in each arm, adding up to 452 participants for the study. The assumption that 18% of the participants in the BSC arm would meet the composite primary outcome was based on the best available evidence at the time of designing the trial.²⁴

Descriptive analysis was done by tabulation of data and presentation of continuous variables as mean and standard deviation (SD) or median and interquartile range (IQR), as appropriate, and categorical variables as proportions.

Univariate analysis was done by Chi-squared test to assess the effect of intervention on the composite primary outcome. To adjust for the difference in BSC by trial sites and clustering of patients in some sites, a multilevel logistic regression was done with trial sites taken as the random effect variable along with adjustment for the unequal distribution of diabetes mellitus between the intervention and control arms. Changes in continuous variables like oxygen requirement (FiO2), laboratory parameters (biomarker levels, NAb titres) over the period of hospital stay were compared between both arms by using generalized estimating equations. CRP and D-Dimer levels were categorized as high when levels were >41.6 mg/L and ≤1 mg/L, respectively. To assess viral clearance, the proportion of participants with SARS-CoV-2 viral RNA negativity was compared between the arms on day 3 and day 7 using the Chi-squared test.

The median score on the WHO Ordinal Scale was plotted for the two trial arms for days 0, 1, 3, 5, 7, and 14.

Post-hoc subgroup analysis was done to compare the composite outcome between participants who received CP with detectable NAb and control arm. Patients receiving CP with NAb titre >1:80 were compared with control for the primary outcome. Stratified analysis was done for the primary outcome between intervention and control arms based on strata such as detectable NAb at enrolment in participants, and duration of symptoms at enrolment. To assess the effect of transfusing CP early in the disease, subgroup analysis for the composite outcome was conducted in participants who had symptoms for less than or equal to 3 days at enrolment.

An intention-to-treat analysis (ITT) was done after imputing the missing composite outcomes as progression to severe disease or mortality. Data were collected in structured paper case record forms (CRF) and then entered in the Research Electronic Data Capture system (REDCap, Version 8.5 Vanderbilt University, Nashville, TN). Data analysis was done using STATA v14 (College Station, Texas, USA). An independent Data and Safety Monitoring Board (DSMB) oversaw the study. The trial protocol was registered with the Clinical Trial Registry of India (CTRI); registration number CTRI/2020/04/024775.

Role of funding source

This multi-centric study was funded by ICMR, an autonomous Government-funded medical research council. The National Task Force for COVID-19, a committee formed by ICMR to respond to the pandemic has reviewed and approved this study. The Central Implementation Team at ICMR was responsible for study design, study coordination, data analysis, data interpretation and writing of the report. Patient enrolment, data collection and actual conduct of the study was done at public and private hospitals independently and the investigators in ICMR had no role in it. The funding source has no financial interest in the investigational product. The corresponding author at ICMR had access to all the data, is the guarantor for the current work and holds final responsibility for the decision to submit for publication.

Results

A total of 1210 patients admitted across 39 trial sites were screened between 22nd April to 14th July 2020; 464 patients were randomized into intervention or CP +BSC arm (n=235) and control or BSC arm (n=229). Outcome at 28 days was not available for 2 patients (one each in intervention and control arm) who were lost to follow-up after discharge from hospital; 9 patients (5 in intervention and 4 in control arm) withdrew consent after randomization. All 464 patients have been included in the intention-to-treat analysis.

Baseline demographic and clinical characteristics were similar across the trial arms, except for prevalence of diabetes mellitus and cough. (Tables 1 and 2) Patient management across the trial arms was similar except for CP therapy. (Table 2)

CP was collected from 433 donors; CP of 262 donors was finally used for the trial. Most of the donors were male (94.3%), with mean (SD) age of 34.3 (9.3) years. The median (IQR) disease duration was 6 (3,11) days and most of the donors (94.2%) had mild disease. Nearly two-thirds (63.6%) of the donors had a NAb titre of more than 1:20 with a median (IQR) titre of 1:40

(1:30,1:80). Plasma was donated after a median (IQR) of 41 (31,51) days from COVID-19 diagnosis by RT-PCR.

There was no difference in the primary outcome across the trial arms on ITT analysis. Thirty-four patients (14.5%) died in the intervention arm and 31 (13.5%) in the control arm; adjusted odds ratio (aOR) was 1.06 [95% CI: 0.61 to 1.83]. Seventeen patients each progressed to severe disease in both arms [7.2% vs. 7.4%; aOR: 1.04; 95% CI: 0.51 to 2.11]. The composite outcome was achieved in 44 (18.7%) patients in the intervention arm and 41 (17.9%) in the control arm [aOR: 1.09; 95% CI: 0.67 to 1.77]. (Table 3)

The proportion of patients with resolution of shortness of breath and fatigue at day 7 were higher in the intervention arm, whereas fever and cough resolution were not different in the two groups. (Table 4) The median (IQR) absolute reduction in Fio2% on days 3 [5 (0,12) vs. 3.7 (0,9), p=0.04], and 5 [9 (3,17) vs. 7 (0,14), p=0.04] from the day of enrolment was significantly more in the intervention as compared to control arm. At 7 [CP+BSC: 11 (6,18) vs. BSC: 9.5 (6,18), p=0.48;] and 14 days [CP+BSC: 14 (9,19) vs. BSC: 12 (6,19), p=0.18;] post enrolment, the change in FiO2% from day of enrolment was similar between the two arms. The negative conversion of SARS-CoV-2 viral RNA at day 7 post-enrollment was significantly higher in the CP arm compared to the BSC arm. (Table 4)

Total and post-enrollment duration of respiratory support, proportion of patients requiring invasive ventilation, and proportion of patients requiring vasopressor support were not different between the trial participants in two arms (Table 4). Among the 38 participants who required invasive ventilation, only two participants survived till 28 days post enrolment. The average levels of inflammatory markers over a period of 7 days from enrolment, showed no statistically significant difference between the two arms [LDH (β =8.9, 95%CI-0.53, 70.9), ferritin (β =30.59, 95%CI-51.36, 112.55). There was no difference in WHO ordinal scale for clinical improvement between the two arms at any time point of observation.

In the trial participants who received CP, minor adverse events of pain in local infusion site, chills, nausea, bradycardia and dizziness was reported in one patient each. Fever and tachycardia were reported in three patients each. Dyspnoea and intravenous catheter blockage were noted in two participants each. Mortality was assessed as possibly related to CP transfusion in 3 patients (1.3%).

Stratified analysis was done by symptom duration at enrolment. The composite outcome was not different between the intervention and control arms for patients with symptom duration less than or equal to 3 days at enrolment [n=24, aOR: 0.59 (95% CI: 0.28, 1.24)]. Titres of NAb in transfused CP were available in 224 out of 235 participants in the intervention arm; 160 (71.4%) participants received at least one unit of CP with detectable NAb. The primary outcome was not different between the subgroups of intervention arm patients receiving CP with detectable NAb titres (n=160) or CP with NAb titre \geq 1:80 (n=68) or CP with no detectable NAbs (n=64) and the control arm (Table 3).

NAb titres were measured in 418 trial participants; 348 (83.2%) had detectable NAb at enrolment. The median (IQR) NAb titre at enrolment was 1:90 (1:30,1:240). In enrolled participants with detectable NAb at baseline, the CP and control groups were not different in

terms of the composite primary outcome [29 (15.7%) vs. 27 (16.6%), aOR: 1.01 (95%CI: 0.56,1.81)]. In patients with undetectable NAb at baseline (n=70), no difference of composite primary outcome could be discerned [9 (30%) vs. 10(25%), aOR: 1.75 (95%CI: 0.41,7.51)].

Discussion

The PLACID trial results indicate that there was no difference in 28-day mortality or progression to severe disease among moderately ill COVID-19 patients treated with CP along with BSC compared to BSC alone. Additionally, there were no differences in outcomes between study participants receiving CP with detectable NAb titres compared to BSC alone; or between those receiving CP with NAb titres more than or equal to 1:80 and those receiving BSC alone. CP therapy was associated with a higher resolution of symptoms like shortness of breath and fatigue on day 7. CP use was also associated with reduction in FiO2 requirement on day 3 and 5 but not in the duration of respiratory support. There was a higher proportion of negative conversion of viral RNA on day 7 post enrolment in intervention arm. However, it did not demonstrate anti-inflammatory properties as we could not detect any difference in the levels of inflammatory markers such as ferritin, CRP, D-Dimer or LDH between the two arms.

A recent Cochrane review, including 20 studies [1 RCT, 3 controlled non-randomized study of intervention (NRSI), 16 non-controlled NRSIs], concluded that there is uncertainty regarding effectiveness of CP in improving mortality or clinical improvement in COVID-19 patients. In a randomized controlled trial conducted from China, Li and colleagues studied 103 patients with severe and life-threatening COVID-19 and reported no effect on time to clinical improvement. Their subgroup of 45 patients with severe disease, similar to patients with moderate disease in our study, demonstrated increased clinical improvement in their CP group. The ConCOVID trial from the Netherlands, prematurely terminated after enrolling 86 patients, could not find any effect on mortality at 60 days, hospital stay or 15-day disease severity. A large observational study advocated the usefulness of CP in COVID-19, stating that the 7-day and 30-day mortality were lower in those who received CP within 3 days of symptom onset. However, the absence of a controlled comparison weakens these findings as evidence of efficacy. Although underpowered, we did not find any benefit of administration of plasma within 3 days of symptom onset.

Our results mirror the experience of the ConCOVID trial, where 79% of the participants had detectable antibodies at baseline. On the other hand, the NAb titres in CP in our study was similar to the results by Long et al, who found 13-40% patients turned seronegative in the early convalescent phase. In a 175-patient series, Wu et al documented that 30% of patients generated very low levels of NAb with titres correlating to increasing age and disease severity. We found participants had higher antibody positivity and median NAb titres than CP donors. The difference in age and severity of illness, with donors being younger and having milder disease, could have driven this difference. While all COVID-19 survivors were encouraged to donate plasma, an overwhelming majority of the donors were only mildly sick, young survivors. Recovered patients who had moderate or severe disease were generally reluctant to return to hospitals for plasma donation. This has major implications for obvious operational reasons as CP therapy for COVID-19 gets scaled up as a component of COVID-19 management strategy not only in India but also globally.

There was no difference in NAb titres in the two arms despite CP transfusion. This suggests that there may not be any benefit of CP collected from young mild COVID -19 recovered donors to moderate to severely sick elderly patients who have a robust antibody response.

The early conversion of viral RNA negativity in intervention arm aligns with published evidence, and further supports the fundamental hypothesis that CP exerts virus neutralization effects. ^{11,13} However, the goal of getting better clinical outcomes remained elusive for us. We did not find evidence to support the immunomodulator functions of CP as we could not demonstrate differences in the levels of inflammatory markers. This could potentially explain why CP had no difference in primary outcome despite early SARS-CoV-2 viral RNA negativity.

CP transfusion was deemed to be safe in our study; minimal non-life-threatening adverse events were reported. Three deaths could possibly be related to CP transfusion, which is comparable to the other larger reports of safety of CP use in COVID-19.¹² Possible is defined here as a clinical event which occurred within 6 hours of CP transfusion, but could also be explained by worsening COVID-19.²³

The PLACID trial was conducted to generate context-specific evidence relevant to all stakeholders, including policymakers, healthcare providers, and patients. To achieve this, expression of interest was invited from hospitals across the country and not limited to a few centres of excellence. Hospitals were chosen both from the public and private sectors, lending heterogeneity in infrastructure, and wide socio-cultural-economic representation of study participants, with a large range of co-morbidities and presenting features. The BSC represented the care standards likely to be provided in a real-world setting. While this approach could have impacted the internal comparability across sites, we feel this lends the trial more generalizability, approximates real-world scenarios more closely and places our study closer to the pragmatic trials across the methodological spectrum of clinical trials.²⁸

The PLACID trial has several limitations. Being an open-labelled study, it was susceptible to anchoring bias in treating physicians in outcome ascertainment. This may be reflected in the higher resolution of subjective symptoms like shortness of breath and fatigue noted in intervention arm. The trial was conducted in 39 hospitals across the country with some level of heterogeneity across the trial sites in terms of BSC and participant enrolment. The biomarker assays for ferritin, LDH, CRP and D-dimer were conducted with products from different manufacturers. Also, as the pandemic was in different stages across the country, the enrolment strength varied from site to site with a possibility of selection bias arising due to clustering of enrolment. We attempted to alleviate this bias by statistically adjusting the primary outcome for trial sites. Further, the discharge criteria for COVID-19 was based on government guidelines and not on clinician discretion and patient condition, hence we chose not to analyse this as a secondary outcome. We could not measure the antibody titres in CP before transfusion, since validated, reliable, commercial tests for qualitative or quantitative antibody measurement were not available at the time of commencement of this trial. However, this remains a close approximation of the manner in which CP therapy has largely been deployed in regions with limited laboratory capacity.

Use of CP as a treatment modality for COVID-19 has received authorisation for off-label use in India.²⁹ This authorization has been paralleled by questionable practices such as calls for donors

on social media, and the sale of CP on the black market with exorbitant price tags in India.³⁰ Additionally, although CP is a safe therapeutic modality, plasmapheresis, plasma storage and NAb measurement are all resource-intensive processes, with limited number of institutes in the country having the capacity to undertake these activities in a quality-assured manner.

Although the use of CP seemed to improve resolution of shortness of breath and fatigue, reduce FiO2 requirement in the first week and led to higher negative conversion of viral RNA, this did not translate into reduction in 28-day mortality or progression to severe disease in moderate COVID-19 patients. Areas of future research could include effectiveness of CP among NAb naïve patients and the use of CP with high NAb titres.

Contributors: Patient enrollment, conduct of study, clinical care and data collection:

Madras Medical College, Chennai: BL, SS, SAMK, VR, AS, PB, RSUM, RJ, SR.

SMS Medical College, Jaipur: SB, SB, AS, AP, AH, GR.

Sir H.N Reliance Foundation Hospital and Research Centre: VK, KK, JR, DR, EP, NB, MHP, RJV.

Sri Aurobindo Institute of Medical Science, Indore: RD, SP, AT, SJ, RK.

Smt. NHL Municipal Medical College, Ahmedabad: JRK, NNS, NMS, HMP, CKS, MNP, SS, SHS, TM, VRB.

Topiwala National Medical College and BYL Nair Hospital: RDS, KJ, FE, SA, RB, AMN, TM, VK, RW, NV.

Gandhi Medical College, Secunderabad: RRM, BTC, AVS, AKM, KH, KN, KS, TRC, KTR, JV.

Government Institute of Medical Science, Noida: SS, RU, SB, RP, SS, BRG.

Gandhi Medical College, Bhopal: SD, RS, PD, RM, DC, JL, UMS, JLM.

ABVIMS & RML Hospital, New Delhi: KC, AS, VK, RK, PK, BPA, KKG, AG, PS, SD.

Satguru Pratap Singh hospitals, Punjab: AJ, MJJ, ASD, RK, NS, NK, DK, RK, RM, GS, JK, RPS, RB

Kasturba Hospital: SP, OS, JS, MD, SU.

Rajarshree Chhatrapati Shahu Maharaj Govt Medical College: VAF, VB, RM, SY

All Institute of Medical Sciences, Jodhpur: SM, AB, MKG, GKB, VN, PBA, MN, PS, RN

Post Graduate Institute of Medical Education and Research, Chandigarh: NSK, PM, RS, MPS, NS, SS, RH, VS, LNY, PVML

All Institute of Medical Sciences, Patna: NS, DB, NK

Byramjee Jeejeebhoy Medical College, Pune: MT, SS, NK, SS, LN, SJ, RK, SG

ESIC Medical College and Hospital, Faridabad: NS, NV, AD; Clinical Development Services Agency: MB, NW

Smt. Kashi Bai Navale Medical College: SB, SD, VW, AK, TY

Karnataka Institute of Medical Sciences, Hubballi: RSK, PR, KY, PG, VM, MS, MHN

Lady Hardinge Medical College and SSK Hospital, New Delhi: AG, RS, SP, AP, PG, SS

King George's Medical University, Lucknow: DHR, CT, SP, PM, AW, VK

Byramjee Jeejeebhoy Medical College, Ahmedabad: KU, NB, NS, MS, TP

Mahatma Gandhi University of Medical Sciences Technology, Jaipur: RMJ, AJ, SS, PR, NG

Government Medical College, Surat: TCP, MGS, JP, YRS, MJ

GMERS Medical College and Hospital, Gotri, Vadodara: VG, MS, RR, IN

Sumandeep Vidyapeeth and Dhiraj Hospital, Vadodara: PRJ, ADS, GY, AJ, RKG

Sri Venkateshwara Institute of Medical Sciences, Tirupati: KVSB, BSB, AM, BV, KCS

Kurnool Medical College, Kurnool: SD, KN, CA, GB, RRK, PC

Madurai Medical College, Madurai: MN, MS, DPK, FR

Government Medical College, Bhavnagar: SJP, PJA, KPJ, PHS, MB

MGM Indore: MB, AY, MG, NR, DC

Poona Hospital and Research Centre: VKK, DP, SM, CDS, VT

Super Specialty Pediatric Hospital and Post Graduate Teaching Institute, Noida: SA, DKG, SD

SN Medical College, Agra: NC, ASC

Christian Medical College, Vellore: JJM, SK, DD

Aditya Birla Memorial Hospital: RS, VD, YA, SA

RD Gardi Medical College, Ujjain: AP, MP, AS

Seth GS Medical college and KEM Hospital, Mumbai: JS, KJ, SB; National Institute of Immunohaematology: MM, RMY

Lokmanya Tilak Municipal Medical College & General Hospital, Mumbai: NDK, YAG, LN, SM

Study design, data analysis, data interpretation and manuscript writing team: AA, AM, GK, PC, TB, SD, PM.

Data Management Team: KK, RS.

Generation of randomization sequence: VSK.

Central Implementation Team: AA, AM, GK, AT.

Laboratory Analysis Team: GD, SS, RG, AS, DP, CP, SS, KJ, HK, PDY, GS, PA.

Declaration of interest: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare that TB is a member of the National Task Force for COVID-19 which approved the protocol. AM, AA, GK, AT, TB, VS, KK, RS, SD, GD, SS, RG, AS, DP, CP, SS, KJ, HK, PDY, GS, PA, MM, RMY are employed with ICMR, the funding source for the trial. PC was an employee of ICMR during the trial. The funding source (ICMR) has no financial interest in the investigational product. No other author has any competing financial or non-financial interest.

Acknowledgement: We wish to acknowledge the following people:

Dr. Santanu Kumar Tripathi, Colonel Rajat Jagani, Prof. L Jeyaseelan, Dr. MS Jawahar and Dr. Suman Kumar Pramanik were members of the independent Data and Safety Monitoring Board.

Dr. S. Devika for helping with study images.

Mr. Jagdish Rajesh, Dr. R Lakshminarayanan and Ms Cosmic Priyanka Singh for their constant administrative support at ICMR Headquarters.

Ms Rekha Dubey, Dr. Rajshekhar Iyer, Dr. Naveen Dutt, Dr. Maya Gopalakrishnan, Dr. Deepak Kumar, Dr. PK Singh, Dr. CM Singh, Dr. Urmika Dholiya, Dr. Vrushti Doshiyad, Dr. Mudita Ravani, Dr. Anand Zachariah, Dr. Binila Chacico, Dr. Dheeraj Kumar, Dr. Shalini Shukla, Dr. Indal Chauhan, Dr. Aruna Kumar, Dr. A.K Shrivastava, Dr. MD Dawood Suleman, Dr. K. Padmamalini, Dr. B. Sheshadri, Dr. Igbal Ahmed, Dr. Vijay Shah, Dr. Kedar, Dr. Tejas Patel, Dr. Tarang Gianchandani, Dr. Chetan B Bhatt, Ms. Ayushi Gianchandani, Dr. Hemant Deshmukh, Dr. Swait Kulkarni, Dr. Gita Nataraj, Dr. Virendra Atam, Professor Amita Jain, Professor Mahendra Lal Brahmbhatt, Dr. Ramalingappa Antaratani, Dr. Iswar S.Hasabi, Dr. Sachin Hosakatti, Dr. Vikas Chandra Swarnkar, Dr. Ganesh Narain Saxena, Dr. Ashina Singla, Dr. R. Chitraa, Dr. CS Sripriya, Dr. J Bharathi Vidhya Jayanthi, Dr. K Ramadevi, Dr. M Chitra, Dr. G Shanthi, Dr. Jagat Ram, Dr. Govardhan Dutt Puri, Ms Richa Pandey, Dr. KK Talwar, Dr. Bishav Mohan, Dr. Sandeep Kaushal, Dr. Loveena Oberoi, Dr. Lalit Kumar Garg, Dr. Rupinder Bakshi, Dr. Kanwaljit Kaur, Dr. Sarabjeet Sharma, Dr. Harjot Kaur, Dr. Gurinder Mohan, Dr. Sunil Chawla, Dr Sarajeet Sharma, Professor Neelam Marwaha, Dr. Ravinder Garg, Dr. Shipa Arora, Dr. Avneet Kaur, Dr. Rajesh Bhaskar, Dr. Gagandeep Singh Grover, Dr. Shilpa Arora, Dr. Sandeep Kaushal, Dr. Rama Gupta, Dr. Prabhat Mehta, Dr. Sushmita Tripathi, Dr. Sachin Dhanrale, Dr. Shreetoma Datta, Dr. Snehal Bachuwar, Dr. Radheshyam Chejara, Dr. Uday Singh Meena, Dr. Girraj Prasad Mathuria, Dr. Dharmendra Kumar Singh, Dr. Prabhat Aggarwal, Dr. Nita Radhakrisnan, Dr. Ankur Goyal, Dr. J.Sangumani, Dr.Senthil and Dr. M.Suresh Kumar helped us enrol participants at the study sites.

Dr. Nitin M Nagarkar, Dr. MD Sabah Siddiqui, Dr. Ramesh Chandrakar, Dr. CH Srinivasa Rao, Dr. Rajiv Kumar B, Dr. Emine A Rahman, Dr. Abhishek B, Dr. Anusha Cherian, Dr. Tamilarasu Kadhiravan, Dr. Maanas Bhaskar, Dr. Aseem K Tiwari, Dr. Geet Aggarwal, Dr. Swati Pabbi, Dr. Arti Trivedi, Dr. Krupal Pujara, Dr. Shailesh Mundhava, Dr. Sudha Ramalingam, Dr. A Murali, Dr. Karthikeyan, Dr. Anjali Sharma, Dr Nandini Duggal, Dr. Mala Chabbra, Dr. Taruna Bansal, Dr. Anupam Verma, Dr. Rahul Katharia, Dr. R.K Dhiman, Dr. S. Alagesan, Dr. SA Manimala, Dr. J Ravishankar, Dr. Inbanathan.J, Dr. Vikas Laxman, Dr. Bharath.M.S, and Dr.Madhukumar.R for their constant support to the study.

Copyright for publication: The Corresponding Author grants on behalf of all authors a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.

Data Sharing Statement: Individual patient level data, collected in connection with the PLACID Trial, along with a data dictionary defining the variable fields has been developed and is available with the corresponding author. De-identified participant level data with data dictionary, or a sub-set thereof, may be made available upon written request to the corresponding author. Additional documents, including the study protocol, statistical analysis plan have been made available as supplementary files within the original submission. Results of secondary or sub-group analyses will be provided on request. Data will be made available, upon request once the trial is published. Data requests should be accompanied by a brief proposal outlining the analysis plan, which may be carried out with investigator support. A signed data access agreement may be needed to ensure data safety and compliance with national rules regarding data sharing.

What is already known on this topic

Till date, multiple small case-series, one large observational study with over 35,000 patients, and two randomized clinical trials have been published on the utility of convalescent plasma in management of COVID-19. Whilst the observational studies suggested clinical benefits in recipients of convalescent plasma, the trials were stopped early, and they failed to ascertain any mortality benefit associated with convalescent plasma therapy in COVID-19 patients.

What this study adds

In settings with limited laboratory capacity, convalescent plasma does not reduce 28-day mortality or progression to severe disease in moderately ill, hospitalized COVID-19 patients. It was associated with resolution of shortness of breath fatigue on day 7, reduction in supplemental oxygen requirement on day 3 and 5 and early negative conversion of SARS-CoV-2 viral RNA. The effectiveness of convalescent plasma as a potential therapeutic modality for moderately ill COVID-19 patients is limited.

References

- 1 Casadevall A, Joyner MJ, Pirofski L. SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy. J Clin Invest 2020; published online July 7. DOI:10.1172/JCI139760.
- 2 Rojas M, Rodríguez Y, Monsalve DM, et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun Rev 2020; 19: 102554.
- 3 Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med 2010; 38: e66-73.
- 4 van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med 2016; 374: 33–42.
- 5 Cheng Y, Wong R, Soo Yoy, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24: 44–6.
- Devasenapathy N, Ye Z, Loeb M, et al. Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis. CMAJ 2020; 192: E745–55.
- Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 2020; published online June 18. DOI:10.1038/s41586-020-2456-9.
- 8 Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA 2020; published online March 27. DOI:10.1001/jama.2020.4783.
- Abolghasemi H, Eshghi P, Cheraghali AM, et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study. Transfus Apher Sci 2020; published online ahead of print, Jul 15. DOI:10.1016/j.transci.2020.102875
- Hegerova L, Gooley TA, Sweerus KA, et al. Use of convalescent plasma in hospitalized patients with COVID-19: case series. Blood 2020; 136: 759–62.
- 11 Xia X, Li K, Wu L, et al. Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion. Blood 2020;136(6):755–9.
- Joyner MJ, Bruno KA, Klassen SA, et al. Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo Clin Proc [Internet]. 2020 Jul 19; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368917/ Accessed on 25 Aug 2020.
- Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients with Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA 2020; published online June 3. DOI:10.1001/jama.2020.10044.

- Gharbharan A, Jordans CCE, Geurtsvan Kessel C, et al. Convalescent Plasma for COVID-19. A randomized clinical trial. medRxiv 2020; 2020.07.01.20139857.
- 15 Piechotta V, Chai KL, Valk SJ, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev 2020; 7: CD013600.
- Available at https://ec.europa.eu/health/sites/health/files/blood_tissues_organs/docs/guidance_plasma_covid1 9_en.pdf Accessed on 17 Aug 2020.
- Guidelines on Clinical Management of COVID-19 v.3. Ministry of Health and Family Welfare; Government of India. 2020. Available from: https://www.mohfw.gov.in/pdf/ClinicalManagementProtocolforCOVID19.pdf Accessed on 25 Aug 2020.
- Department of Health and Family Welfare, Ministry of Health and Family Welfare; Government of India. Gazette of India. Available from: https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/NewDrugs_CTRules_2019.pdf Accessed on 25 Aug 2020.
- 19 Epstein J, Burnouf T. Points to consider in the preparation and transfusion of COVID-19 convalescent plasma. Vox Sang 2020 Apr 22:10.1111/vox.12939.
- Wu F, Wang A, Liu M, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv 2020; 2020.03.30.20047365.
- 21 Sarkale P, Patil S, Yadav PD, et al. First isolation of SARS-CoV-2 from clinical samples in India. Indian J Med Res 2020;151:244-50
- WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis 2020;20(8):e192-e197.
- 23 Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255-1259.
- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062.
- Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol 2020;127:104370.

- Joyner MJ, Senefeld JW, Klassen SA, et al. Effect of convalescent plasma on mortality among hospitalized patients with covid-19: initial three-month experience. MedRxiv. https://www.medrxiv.org/content/10.1101/2020.08.12.20169359v1.full.pdf.
- 27 Long, Q., Tang, X., Shi, Q. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 26, 1200–1204 (2020). https://doi.org/10.1038/s41591-020-0965-6
- 28 Ford I, Norrie J. Pragmatic Trials. N Engl J Med. 2016;375(5):454-463.
- 29 Central Drugs Standard Control Notice. Available at: organisation https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=NjA0Mw== Accesses on 25Aug 2020.
- Khan J, Hizbullah M, Jain N. Coronavirus pandemic fuels black-market for plasma of recovered patients. India Today. [newspaper on the Internet]. July 22, 2020. Available on: https://www.indiatoday.in/india/story/exclusive-coronavirus-pandemic-fuels-black-market-for-plasma-of-recovered-patients-1703332-2020-07-22 Accessed on 25 Aug 202

Table 1: Demographic and baseline characteristics of the study participants, n=464

	Best Standard of Care arm, n=229	Convalescent Plasma arm, n=235
Age in yrs, Median (IQR)	52 (41,60)	52 (42, 60)
Gender, male, n(%)	177 (77.3%)	177 (75.3%)
BMI, kg/m², mean (SD)	26.1 (4.2%)	26.2 (4.3%)
Comorbidities, n(%)	147 (64.2%)	167 (71.1%)
Diabetes mellitus	87 (38.2%)	113 (48.1)
Hypertension	81 (35.5%)	92 (39.1%)
Coronary artery disease	17 (7.4%)	15 (6.4%)
Obesity	17 (7.4%)	16 (6.8%)
#Tuberculosis	10 (4.4%)	9 (3.8%)
Chronic kidney disease	9 (3.9%)	8 (3.4%)
Chronic obstructive pulmonary disease	7 (3.1%)	8 (3.4%)
Cerebrovascular disease	1 (0.4%)	3 (1.3%)
Liver Cirrhosis	2 (0.9%)	0
Cancer (History)	0	1 (0.4%)
Ever smoker, n(%)	18 (7.9)	19 (8.1)
Blood Group, n(%)		
A	51(22.3%)	55(23.4%)
В	83(36.3%)	87(37.1%)
0	83(36.2%)	79(33.6%)
AB	12(5.2%)	14(5.9%)

Symptom onset to admission, days, Median (IQR)	4 (3,7)	4 (3,7)
Symptom onset to enrolment, days, Median (IQR)	8 (6,11)	8 (6,11)
*Detectable Neutralisation antibody titre, n(%) n=418	163 (80.3)	185 (86.1)

^{*}Data not available for all randomized patients # Only 2 patients had active TB, one in each arm BMI: body mass index; IQR: interquartile range

Table 2: Clinical and laboratory parameters of the trial participants at baseline and medications received during hospitalization, n=464

	Best Standard of Care arm (n=229)	Convalescent Plasma arm (n=235)
Shortness of Breath, n(%)	208 (90.8%)	215 (91.5%)
Fever, n(%)	85(37.1%)	77(32.8%)
Cough, n(%)	167(72.9%)	149(63.4%)
Fatigue, n(%)	182/229 (79.5%)	183/234 (78.2%)
X-ray findings, n(%), n=432		
Ground glass opacity	29 (13.5%)	27 (12.4%)
Local patchy shadows	9(4.2%)	12(5.5%)
B/L patchy shadows	139(64.9%)	140(64.2%)
Interstitial abnormalities	4(1.9%)	3(1.4%)
B/L white out lung	2(0.9%)	2(0.9%)
SpO2 (%) on room air, mean (SD), n=420	88.5(4.1)	88.1 (4.4)
FiO2 required to maintain SpO2 >92%, mean (SD),	37.4 (11.4)	39.04 (13.1)
n=462		
PaO2/FiO2, mean (SD)	251.6 (39.5)	255.4 (42.1)
Haemoglobin (g/dl), mean (SD)	12.5 (1.8)	12.5 (2.1)
WBC count (Cells /mm³), median (IQR)	8500 (6500,11200)	8480 (6110,11460)
Neutrophil-Lymphocyte Ratio (NLR), median (IQR)	5.5 (3.4, 9.4)	5.5 (3.5, 10)
Ferritin, ng/mL, Median (IQR), n=448	539.5 (328.3, 873)	529.8 (278.6, 956)
LDH, IU/L, Median (IQR), n=450	458.6 (342.5, 638.5)	473.5 (335, 661)
High CRP, n(%), n=395	97 (50%)	100 (49.7%)
High D-Dimer, n(%), n=399	68 (34.7%)	82 (40.4%)
WHO Ordinal scale, n(%), n=463		

4	181(79.0%)	180 (76.9%)
5	47(20.5%)	54(23.1%)
6	1(0.4%)	0
Medications, n(%)		
Hydroxychloroquine	155 (68.3%)	159 (67.7%)
Remdesivir	13 (5.9%)	7 (3.2%)
Lopinavir/Ritonavir	30 (13.6%)	36 (16.1%)
Methylprednisolone	114 (49.8%)	123 (52.3%)
Dexamethasone	30 (13.1%)	23 (9.8%)
Hydrocortisone	5 (2.2%)	4 (1.7%)
Tocilizumab	26 (12.7%)	16 (7.2%)
Heparin (UFH/LMWH)	170 (76.6%)	178 (77.7%)
Azithromycin	140 (65.1%)	156 (69.3%)
Intravenous Immunoglobulin	0	1 (0.4%)
Other Antibiotics	196 (87.5%)	204 (87.5%)

High CRP: Levels above 41mg/L; High D-dimer: Levels above 1mg/L

FiO2: fraction of inspired oxygen; PaO2: Partial pressure of Oxygen in arterial blood; WBC: White Blood Cells; LDH: lactate dehydrogenase; CRP: C-reactive protein; WHO Ordinal scale: World Health Organization ordinal scale; UFH: unfractionated heparin; LMWH: Low molecular weight heparin.

Table 3: Comparison of primary outcomes between intervention and control arms

Best Standard of Car	re Convalescent Plasma	a Convalescent Plasma arn	n Convalescent Plasma	
arm	arm*	(with detectable NAbs in	narm (with NAbs≥1:80	arm (with undetectable NAb in
N=229	N=235	CP)*	in CP)*	CP)*
		N=160	N=67	N= 64
All-cause mortality at 28 31(13.5%)	34 (14.5%)	22 (13.8%)	10 (14.9%)	12 (18.7%)
days				
aOR (95%CI)	1.05 (0.61,1.83)	0.93 (0.49, 1.70)	0.93 (0.39, 2.21)	1.49 (0.68, 3.23)
Progression to severe 17 (7.4%)	17 (7.2%)	11 (6.8%)	6 (8.9%)	6 (9.4%)
disease (P/F ratio <100)				
aOR (95%CI)	1.04 (0.51, 2.11)	0.91(0.41, 2.02)	1.25 (0.45, 3.41)	1.33 (0.49, 3.59)
Composite outcome 41 (17.9%)	44 (18.7%)	27 (16.9%)	12 (17.9%)	13 (20.3%)
aOR (95%CI)	1.09 (0.67, 1.77)	1.04 (0.61,1.78)	0.92 (0.43,1.97)	1.19 (0.59, 2.42)

aOR: adjusted odds ratio; NAb: neutralizing antibodies; CP: Convalescent plasma

^{*}All comparisons were done with best standard of care, adjustment done for presence of diabetes mellitus and trial site

Table 4: Comparison of secondary outcomes between intervention and control arms

	Basic Standard of Care arm, N=229	Convalescent Plasma arm, N=235	P Value
Resolution of shortness of breath on day7, n (%)	/	140 (76.5%)	0.02
Resolution of fever on day7, n (%)	65 (91.5%)	67 (98.5%)	0.06
Resolution of cough on day7, n (%)	111 (75.5%)	102 (79.7%)	0.4
Resolution of fatigue on day7, n (%)	92 (60.1%)	114 (73.1%)	0.02
Absolute change in Fio2 on day 3	3.7 (0,9)	5 (0,12)	0.04
Absolute change in Fio2 on day 5	7 (0,14),	9 (3,17)	0.04
Absolute change in Fio2 on day 7	9.5 (6,18),	11 (6,18)	0.48
Negative conversion of SARS-CoV-2 viral RNA on day 3, n=350, n(%)	67 (36.2%)	82 (43.4%)	0.15
Negative conversion of SARS-CoV-2 viral RNA on day 7, n=374, n(%)	94 (54.6%)	121 (67.9%)	0.01
Total days of hospital stay, Median (IQR)	13 (10,18)	14 (10,19)	0.51
Total days of respiratory support, Median, IQR	,	9 (6,13)	0.67
Days of respiratory support post-enrolment, Median (QR)	6 (4,10)	6 (3,9)	0.46
Invasive mechanical ventilation during hospital stay, n(%)	20 (8.9%)	18 (7.8%)	0.68
Vasopressor support after enrolment, n(%)	8 (3.6%)	10 (4.4%)	0.7

All changes are measured from day of enrolment; FiO2: Fraction of inspired oxygen